JPH02138292A - 2'-methylidenepyrimidine nucleoside compound and drug use thereof - Google Patents
2'-methylidenepyrimidine nucleoside compound and drug use thereofInfo
- Publication number
- JPH02138292A JPH02138292A JP1217719A JP21771989A JPH02138292A JP H02138292 A JPH02138292 A JP H02138292A JP 1217719 A JP1217719 A JP 1217719A JP 21771989 A JP21771989 A JP 21771989A JP H02138292 A JPH02138292 A JP H02138292A
- Authority
- JP
- Japan
- Prior art keywords
- yield
- compound
- methylidene
- ethyl acetate
- deoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 nucleoside compound Chemical class 0.000 title claims description 14
- 239000002777 nucleoside Substances 0.000 title claims description 6
- 239000003814 drug Substances 0.000 title description 3
- 229940079593 drug Drugs 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 70
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 24
- 239000000126 substance Substances 0.000 claims abstract description 15
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 12
- 125000000304 alkynyl group Chemical group 0.000 claims abstract description 12
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical group OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims abstract description 10
- 125000001188 haloalkyl group Chemical group 0.000 claims abstract description 6
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 6
- 150000002367 halogens Chemical class 0.000 claims abstract description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 14
- 239000002246 antineoplastic agent Substances 0.000 claims description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- CBFZRLQZSOMINR-BKPPORCPSA-N 4-amino-5-fluoro-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)-3-methylideneoxolan-2-yl]pyrimidin-2-one Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1C(=C)[C@H](O)[C@@H](CO)O1 CBFZRLQZSOMINR-BKPPORCPSA-N 0.000 claims 2
- 125000006239 protecting group Chemical group 0.000 abstract description 11
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 6
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract description 5
- 229910000147 aluminium phosphate Chemical group 0.000 abstract description 4
- 239000003795 chemical substances by application Substances 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract description 2
- 150000001720 carbohydrates Chemical group 0.000 abstract 5
- APRRQJCCBSJQOQ-UHFFFAOYSA-N 4-amino-5-hydroxynaphthalene-2,7-disulfonic acid Chemical group OS(=O)(=O)C1=CC(O)=C2C(N)=CC(S(O)(=O)=O)=CC2=C1 APRRQJCCBSJQOQ-UHFFFAOYSA-N 0.000 abstract 1
- 230000003327 cancerostatic effect Effects 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 133
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 75
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 66
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 48
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 47
- 239000000203 mixture Substances 0.000 description 45
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 44
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 41
- 239000000741 silica gel Substances 0.000 description 40
- 229910002027 silica gel Inorganic materials 0.000 description 40
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 27
- 239000010410 layer Substances 0.000 description 26
- 239000002904 solvent Substances 0.000 description 25
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 24
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 24
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 22
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 21
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 239000000243 solution Substances 0.000 description 21
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 20
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 20
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 20
- 229910052938 sodium sulfate Inorganic materials 0.000 description 20
- 235000011152 sodium sulphate Nutrition 0.000 description 20
- 238000002844 melting Methods 0.000 description 18
- 230000008018 melting Effects 0.000 description 18
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- 239000003205 fragrance Substances 0.000 description 15
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- 239000012044 organic layer Substances 0.000 description 13
- 229910052786 argon Inorganic materials 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 239000000706 filtrate Substances 0.000 description 12
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 10
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 10
- 238000010828 elution Methods 0.000 description 9
- 238000000921 elemental analysis Methods 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 8
- 238000002425 crystallisation Methods 0.000 description 7
- 230000008025 crystallization Effects 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- WGLPBDUCMAPZCE-UHFFFAOYSA-N Trioxochromium Chemical compound O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 6
- SWLVFNYSXGMGBS-UHFFFAOYSA-N ammonium bromide Chemical compound [NH4+].[Br-] SWLVFNYSXGMGBS-UHFFFAOYSA-N 0.000 description 6
- KRVSOGSZCMJSLX-UHFFFAOYSA-L chromic acid Substances O[Cr](O)(=O)=O KRVSOGSZCMJSLX-UHFFFAOYSA-L 0.000 description 6
- 229910000423 chromium oxide Inorganic materials 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- AWJWCTOOIBYHON-UHFFFAOYSA-N furo[3,4-b]pyrazine-5,7-dione Chemical compound C1=CN=C2C(=O)OC(=O)C2=N1 AWJWCTOOIBYHON-UHFFFAOYSA-N 0.000 description 6
- LSEFCHWGJNHZNT-UHFFFAOYSA-M methyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C)C1=CC=CC=C1 LSEFCHWGJNHZNT-UHFFFAOYSA-M 0.000 description 6
- SNTWKPAKVQFCCF-UHFFFAOYSA-N 2,3-dihydro-1h-triazole Chemical compound N1NC=CN1 SNTWKPAKVQFCCF-UHFFFAOYSA-N 0.000 description 5
- LJQKCYFTNDAAPC-UHFFFAOYSA-N ethanol;ethyl acetate Chemical compound CCO.CCOC(C)=O LJQKCYFTNDAAPC-UHFFFAOYSA-N 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 210000000448 cultured tumor cell Anatomy 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000005576 amination reaction Methods 0.000 description 3
- 239000012300 argon atmosphere Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- RKSLVDIXBGWPIS-UAKXSSHOSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 RKSLVDIXBGWPIS-UAKXSSHOSA-N 0.000 description 2
- VREGLRAFNWMIBM-BKPPORCPSA-N 4-amino-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)-3-methylideneoxolan-2-yl]-5-iodopyrimidin-2-one Chemical compound C1=C(I)C(N)=NC(=O)N1[C@H]1C(=C)[C@H](O)[C@@H](CO)O1 VREGLRAFNWMIBM-BKPPORCPSA-N 0.000 description 2
- PULHLIOPJXPGJN-BWVDBABLSA-N 4-amino-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)-3-methylideneoxolan-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1C(=C)[C@H](O)[C@@H](CO)O1 PULHLIOPJXPGJN-BWVDBABLSA-N 0.000 description 2
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 2
- DDFHBQSCUXNBSA-UHFFFAOYSA-N 5-(5-carboxythiophen-2-yl)thiophene-2-carboxylic acid Chemical compound S1C(C(=O)O)=CC=C1C1=CC=C(C(O)=O)S1 DDFHBQSCUXNBSA-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 238000005903 acid hydrolysis reaction Methods 0.000 description 2
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 238000010531 catalytic reduction reaction Methods 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- GCFHZZWXZLABBL-UHFFFAOYSA-N ethanol;hexane Chemical compound CCO.CCCCCC GCFHZZWXZLABBL-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000009422 growth inhibiting effect Effects 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Chemical class 0.000 description 2
- 150000004682 monohydrates Chemical class 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000000865 phosphorylative effect Effects 0.000 description 2
- 235000019814 powdered cellulose Nutrition 0.000 description 2
- 229920003124 powdered cellulose Polymers 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000007940 sugar coated tablet Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- HGHAWOKGZGDPKH-PNHWDRBUSA-N 1-[(2r,3r,4s,5r)-2-ethynyl-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@@]1(C#C)N1C(=O)NC(=O)C=C1 HGHAWOKGZGDPKH-PNHWDRBUSA-N 0.000 description 1
- QCWBIPKYTBFWHH-FDDDBJFASA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-ethynylpyrimidine-2,4-dione Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C#C)=C1 QCWBIPKYTBFWHH-FDDDBJFASA-N 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- NCZFDEBKMUJQQO-FDDDBJFASA-N 4-amino-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-ethynylpyrimidin-2-one Chemical compound C1=C(C#C)C(N)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NCZFDEBKMUJQQO-FDDDBJFASA-N 0.000 description 1
- RUDYESOPLCFJPW-BKPPORCPSA-N 4-amino-5-bromo-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)-3-methylideneoxolan-2-yl]pyrimidin-2-one Chemical compound C1=C(Br)C(N)=NC(=O)N1[C@H]1C(=C)[C@H](O)[C@@H](CO)O1 RUDYESOPLCFJPW-BKPPORCPSA-N 0.000 description 1
- AIVMOZPINSJJET-BKPPORCPSA-N 4-amino-5-chloro-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)-3-methylideneoxolan-2-yl]pyrimidin-2-one Chemical compound C1=C(Cl)C(N)=NC(=O)N1[C@H]1C(=C)[C@H](O)[C@@H](CO)O1 AIVMOZPINSJJET-BKPPORCPSA-N 0.000 description 1
- QDPAMGCFBHETGN-WCABBAIRSA-N 4-amino-5-ethyl-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)-3-methylideneoxolan-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C(CC)=CN1[C@H]1C(=C)[C@H](O)[C@@H](CO)O1 QDPAMGCFBHETGN-WCABBAIRSA-N 0.000 description 1
- AGFIRQJZCNVMCW-UAKXSSHOSA-N 5-bromouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 AGFIRQJZCNVMCW-UAKXSSHOSA-N 0.000 description 1
- LDCUBKKZHSYQTJ-UAKXSSHOSA-N 5-chloro-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Cl)=C1 LDCUBKKZHSYQTJ-UAKXSSHOSA-N 0.000 description 1
- FHIDNBAQOFJWCA-UAKXSSHOSA-N 5-fluorouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 FHIDNBAQOFJWCA-UAKXSSHOSA-N 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- DDYAZDRFUVZBMM-UHFFFAOYSA-N chloro-[chloro-di(propan-2-yl)silyl]oxy-di(propan-2-yl)silane Chemical compound CC(C)[Si](Cl)(C(C)C)O[Si](Cl)(C(C)C)C(C)C DDYAZDRFUVZBMM-UHFFFAOYSA-N 0.000 description 1
- 125000002603 chloroethyl group Chemical group [H]C([*])([H])C([H])([H])Cl 0.000 description 1
- ZCDOYSPFYFSLEW-UHFFFAOYSA-N chromate(2-) Chemical compound [O-][Cr]([O-])(=O)=O ZCDOYSPFYFSLEW-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- NKRNGKIEDAVMHL-UHFFFAOYSA-L dihydroxy(dioxo)chromium;pyridine Chemical compound O[Cr](O)(=O)=O.C1=CC=NC=C1 NKRNGKIEDAVMHL-UHFFFAOYSA-L 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002431 hydrogen Chemical group 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 239000008311 hydrophilic ointment Substances 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- AZFQCTBZOPUVOW-UHFFFAOYSA-N methyl(triphenyl)phosphanium Chemical compound C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C)C1=CC=CC=C1 AZFQCTBZOPUVOW-UHFFFAOYSA-N 0.000 description 1
- JNMIXMFEVJHFNY-UHFFFAOYSA-M methyl(triphenyl)phosphanium;iodide Chemical compound [I-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C)C1=CC=CC=C1 JNMIXMFEVJHFNY-UHFFFAOYSA-M 0.000 description 1
- XYDYWTJEGDZLTH-UHFFFAOYSA-N methylenetriphenylphosphorane Chemical group C=1C=CC=CC=1P(C=1C=CC=CC=1)(=C)C1=CC=CC=C1 XYDYWTJEGDZLTH-UHFFFAOYSA-N 0.000 description 1
- BDGDWWGTAFXEEW-UHFFFAOYSA-N methylsulfinylmethane;oxalyl dichloride Chemical compound CS(C)=O.ClC(=O)C(Cl)=O BDGDWWGTAFXEEW-UHFFFAOYSA-N 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 125000001038 naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229940127084 other anti-cancer agent Drugs 0.000 description 1
- 229940047091 other immunostimulants in atc Drugs 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960005235 piperonyl butoxide Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明は、すぐれた抗腫瘍作用を有する新規な2°−メ
チリデンピリミジンヌクレオシド化合物およびその医薬
用途に関する。DETAILED DESCRIPTION OF THE INVENTION [Field of Industrial Application] The present invention relates to a novel 2°-methylidenepyrimidine nucleoside compound having excellent antitumor activity and its pharmaceutical use.
(従来の技術および発明が解決すべき課題〕がんによる
死亡が増加している状況下、外科療法にあわせて化学療
法および免疫療法が広く行われている。ここで、化学療
法においては代謝拮抗性抗悪性117i剤としてシトシ
ンアラビノシドや5−フルオロウラシルなどが急性白血
病などに有効であるとして臨床上使用されている。しか
しながら、従来の制がん剤ではいまだに十分満足しうる
治癒効果が得られず、しかも副作用をもたらすなど、様
々な問題があり、各方面からすぐれた制がん剤の開発が
求められている。(Problems to be solved by conventional techniques and inventions) Under the circumstances where cancer deaths are increasing, chemotherapy and immunotherapy are widely used in conjunction with surgical therapy. Cytosine arabinoside and 5-fluorouracil are clinically used as anti-cancer 117i agents as they are effective against acute leukemia.However, conventional anticancer agents still do not have satisfactory curative effects. However, there are various problems such as side effects, etc., and the development of excellent anticancer drugs is required from various fields.
このような状況下、本発明者らは2°−デオキシ−2゛
〜メチリデンシチジンまたはその薬学的に許容されうる
塩を発明した。Under these circumstances, the present inventors invented 2'-deoxy-2'-methylidenecytidine or a pharmaceutically acceptable salt thereof.
しかしながら、2° −デオキシ−2°−メチリデンシ
チジンは溶解性が悪く、その酸付加塩は不安定な為、そ
れらは製剤上満足しうるものではなかった。However, since 2°-deoxy-2°-methylidenecytidine has poor solubility and its acid addition salts are unstable, they have not been satisfactory from a pharmaceutical standpoint.
本発明は、すぐれた抗II瘍作用を有する新規な化合物
およびその医薬用途を提供することを目的とする。An object of the present invention is to provide a novel compound having excellent anti-II tumor activity and its medical use.
本発明者らは、製剤上の問題がなく、制がん剤として有
用な新規化合物を開発すべく研究を重ねた結果、2゛
−メチリデンピリミジンヌクレオシド化合物がすぐれた
抗lI!ITgj作用を有することを見出し、本発明を
完成させた。As a result of repeated research to develop a new compound that is free from formulation problems and is useful as an anticancer agent, the present inventors have found that 2.
-Methylidenepyrimidine nucleoside compounds are excellent anti-II! It was discovered that it has an ITgj effect, and the present invention was completed.
本発明c;t、 ax 、。The present invention c; t, ax,.
(式中、R1はアミノまたは水酸基を示し、R1がアミ
ノの場合、R2はハロゲン、炭素数2〜4個のアルキニ
ルまたは低級アルキルを、R’が水酸基の場合、R1は
炭素数2〜4個のアルキル、炭素数2〜4個のアルキニ
ルまたはハロアルキルを、R3は水素またはリン酸残基
を示す。)により表わされる2”−デオキシ−2°−メ
チリデンピリミジンヌクレオシド化合物またはその塩に
関する。(In the formula, R1 represents an amino or hydroxyl group; when R1 is amino, R2 represents a halogen, alkynyl or lower alkyl having 2 to 4 carbon atoms; when R' is a hydroxyl group, R1 represents a carbon number of 2 to 4 alkyl, alkynyl or haloalkyl having 2 to 4 carbon atoms, and R3 represents hydrogen or a phosphoric acid residue) or a salt thereof.
さらに、本発明は一般式(1)の化合物またはその塩を
有効成分として含有することを特徴とする制がん剤に関
する。Furthermore, the present invention relates to an anticancer agent characterized by containing the compound of general formula (1) or a salt thereof as an active ingredient.
上記−最大(1)中、R2で示されるハロゲンとはフッ
素、塩素、臭素、ヨウ素を、低級アルキルとはメチル、
エチル、プロピル、イソプロピル、ブチル、イソブチル
、第3級ブチルなどを、炭素数2〜4個のアルキルとは
エチル、プロピル、イソプロピル、ブチル、イソブチル
、第3級ブチルなどを、炭素数2〜4個のアルキニルと
はエチニル、1−プロピニル、2−プロピニル、1−ブ
チニル、2−ブチニル、3−ブチニルなどを意味する。In the maximum (1) above, halogen represented by R2 means fluorine, chlorine, bromine, and iodine, and lower alkyl means methyl,
Ethyl, propyl, isopropyl, butyl, isobutyl, tertiary butyl, etc., and alkyl with 2 to 4 carbon atoms include ethyl, propyl, isopropyl, butyl, isobutyl, tertiary butyl, etc., and have 2 to 4 carbon atoms. Alkynyl means ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, and the like.
また、ハロアルキルとはトリフルオロメチル、クロロエ
チルなどを意味する。Further, haloalkyl means trifluoromethyl, chloroethyl, etc.
一般式(1)の化合物の塩としては、R1が水素である
場合には塩酸塩、硫酸塩、臭化水素酸塩、リン酸塩、マ
レイン酸塩、フマール酸塩、酒石酸塩、コハク酸塩、ク
エン酸塩、p−トルエンスルホン酸塩などの酸付加物が
、R″がリン酸残基の場合にはナトリウム塩、カリウム
塩、リチウム塩、カルシウム塩などの金属塩もしくはア
ンモニウム塩などがあげられる。また、本発明には一般
式(I)の化合物またはその塩の水和物(1水和物、1
/2水和物、1/4水和物、3/2永和物)または溶媒
和物も含まれる。When R1 is hydrogen, the salts of the compound of general formula (1) include hydrochloride, sulfate, hydrobromide, phosphate, maleate, fumarate, tartrate, and succinate. , citrate, p-toluenesulfonate, etc., and when R'' is a phosphoric acid residue, metal salts such as sodium salt, potassium salt, lithium salt, calcium salt, or ammonium salt, etc. The present invention also includes a hydrate (monohydrate, monohydrate) of the compound of general formula (I) or a salt thereof.
/dihydrate, 1/4 hydrate, 3/2 hydrate) or solvates.
一般式(1)の化合物において、R1が水酸基である場
合には、その互変異性体としての一般式%式%
テン−5−エチニルウリジンまたは2″−デオキシ−2
°−メチリデン−5−フルオロシチジン−5° −リン
酸があげられる。In the compound of general formula (1), when R1 is a hydroxyl group, the general formula % formula % as its tautomer is ten-5-ethynyl uridine or 2″-deoxy-2
°-Methylidene-5-fluorocytidine-5°-phosphoric acid is mentioned.
本発明の一般式(1)の化合物において、R’が水酸基
である化合物(以下、ウリジン化合物により示す。)は
、たとえば−最大
(式中、R1、R3は前記と同義である。)により表わ
されるウリジン化合物も本発明に包含される。In the compound of general formula (1) of the present invention, a compound in which R' is a hydroxyl group (hereinafter referred to as a uridine compound) is, for example, represented by -max (in the formula, R1 and R3 have the same meanings as above). Also included in the present invention are uridine compounds.
一般式(1)の化合物としては、2°−デオキシ−2′
−メチリデン−5−フルオロシチジン、2°−デオキシ
−2“−メチリデン−5−クロロシチジン、2°−デオ
キシ−2′−メチリデン5−ブロモシチジン、2゛−デ
オキシ−2°−メチリデン−5−ヨウドシチジン、2°
−デオキシ−2”−メチリデン−5−メチルシチジン、
2゜−デオキシー2゛−メチリデン−5−エチルシチジ
ン、2゛−デオキシ−2°−メチリデン−5−エチルウ
リジン、2°−デオキシ−2”−メチリ(式中、Rはハ
ロゲン、アルキル、ハロアルギルまたは炭素数2〜4個
のアルキニルを示す、)により表わされる化合物の糖部
3°位および5゛位水酸基を保護した後、糖部2°位水
酸基を酸化し、ついでウィツテイヒ(llittig)
試薬を反応させて糖部2゛位メチリデン体とし、その後
、糖部3“位および5゛位水酸基の保護基を除去し、必
要に応じ糖部5゛位水酸基をリン酸化することにより製
造される。As the compound of general formula (1), 2°-deoxy-2'
-Methylidene-5-fluorocytidine, 2'-deoxy-2'-methylidene-5-chlorocytidine, 2'-deoxy-2'-methylidene-5-bromocytidine, 2'-deoxy-2'-methylidene-5-iodocytidine , 2°
-deoxy-2”-methylidene-5-methylcytidine,
2゜-deoxy-2゛-methylidene-5-ethylcytidine, 2゛-deoxy-2゛-methylidene-5-ethyluridine, 2゜-deoxy-2''-methyl (wherein R is halogen, alkyl, haloargyl or After protecting the hydroxyl groups at the 3° and 5′ positions of the sugar moiety of the compound represented by (2) representing alkynyl having 2 to 4 carbon atoms, the hydroxyl group at the 2° position of the sugar moiety is oxidized, and then
It is produced by reacting a reagent to form a methylidene at the 2'-position of the sugar moiety, then removing the protecting groups for the hydroxyl groups at the 3'- and 5'-positions of the sugar moiety, and phosphorylating the hydroxyl group at the 5'-position of the sugar moiety, if necessary. Ru.
上記において、糖部3°位および5”位水酸基の保護基
としては、水酸基の保護基として常用されているもので
あればよく、たとえば、アセチル、プロピオニル、ブチ
リル、ベンゾイル、ナフトイルなどのアシル基、エチリ
デン、プロピリデン、イソプロピリデン、ベンジリデン
、シクロへキシリデン、シクロペンチリデン、メトキシ
メチリデン、エトキシメチリデン、ジメトキシメチリデ
ンなどのアセタールまたはケタール型保11!基、ベン
ジル、p−メトキシベンジル、3.4−ジメトキシベン
ジル、ジフェニルメチル、トリフェニルメチル、αもし
くはβ−ナフチルメチル、α−ナフチルジフェニルメチ
ルなどのアルアルキル基、トリメチルシリル、t−ブチ
ルジメチルシリル、メチルジイソプロピルシリル、トリ
イソプロピルシリル、テトライソプロビルジシロキシル
(T I PDS)などのシリル基を例示することがで
きる。In the above, the protecting groups for the hydroxyl groups at the 3° and 5'' positions of the sugar moiety may be those commonly used as protecting groups for hydroxyl groups, such as acyl groups such as acetyl, propionyl, butyryl, benzoyl, and naphthoyl; Acetal or ketal type groups such as ethylidene, propylidene, isopropylidene, benzylidene, cyclohexylidene, cyclopentylidene, methoxymethylidene, ethoxymethylidene, dimethoxymethylidene, benzyl, p-methoxybenzyl, 3.4- Aralkyl groups such as dimethoxybenzyl, diphenylmethyl, triphenylmethyl, α- or β-naphthylmethyl, α-naphthyldiphenylmethyl, trimethylsilyl, t-butyldimethylsilyl, methyldiisopropylsilyl, triisopropylsilyl, tetraisopropyldisiloxyl ( Examples include silyl groups such as T I PDS).
2゛位水酸基の酸化方法としては、クロム酸ピリジン−
無水酢酸の複合体などを用いるクロム酸酸化(A法)も
しくは、塩化オキサリル−ジメチルスルホキシドなどに
より生じる活性化ジメチルスルホキシドを用いる活性化
ジメチルスルホキシド酸化(B法)などを採用すること
ができる。As a method for oxidizing the 2-position hydroxyl group, chromate pyridine-
Chromic acid oxidation using a complex of acetic anhydride (Method A) or activated dimethyl sulfoxide oxidation using activated dimethyl sulfoxide produced from oxalyl chloride-dimethyl sulfoxide (Method B) can be employed.
酸化反応は、化合物1モルに対して1〜10倍モルの酸
化剤の存在下、A法の場合には一10°C〜室温、B法
の場合には−10〜−80℃で1〜10時間反応させる
ことにより実施することができる。The oxidation reaction is carried out in the presence of an oxidizing agent in an amount of 1 to 10 times the mole of the compound, in the case of method A at -10°C to room temperature, and in the case of method B at -10 to -80°C. This can be carried out by reacting for 10 hours.
メチリデン化反応に使用するウィツテイヒ試薬は、具体
的にはトリフェニルホスフィンメチレンがあげられ、使
用直前に、トリフェニルホスホニウム化合物(臭化メチ
ルトリフェニルホスホニウム、ヨウ化メチルトリフェニ
ルホスホニウムなど)と強アルカリ(水素化カリウム、
水素化ナトリウム、n−ブチルリチウム、ナトリウムメ
トキシド、カリウム−L−ブトキシド、ナトリウムアミ
ドなど)から常法に従って調製したものを使用するのが
好ましい、ウィツテイヒ試薬の使用量は化合物1モルに
対して1〜3倍モルから適宜選定できる。The Witzteig reagent used in the methylidene reaction is specifically triphenylphosphine methylene, and immediately before use, it is mixed with a triphenylphosphonium compound (methyltriphenylphosphonium bromide, methyltriphenylphosphonium iodide, etc.) and a strong alkali ( potassium hydride,
It is preferable to use a reagent prepared from sodium hydride, n-butyllithium, sodium methoxide, potassium L-butoxide, sodium amide, etc. according to a conventional method.The amount of Witzteig reagent used is 1 per mole of the compound. It can be appropriately selected from 3 to 3 times the mole.
このようなウィツテイヒ試薬を用いるメチリデン化反応
は、溶媒(テトラヒドロフラン、ジオキサン、エーテル
、ベンゼン、ジメチルスルホキシドなどの単独もしくは
混合溶媒)中、−30〜30°Cで0.5〜20時間反
応させることにより実施することができる。Methylidene reaction using such a Wittich reagent can be carried out by reacting in a solvent (single or mixed solvent such as tetrahydrofuran, dioxane, ether, benzene, dimethyl sulfoxide, etc.) at -30 to 30°C for 0.5 to 20 hours. It can be implemented.
糖部水酸基の保護基除去反応は、使用した保護基に応じ
た酸性加水分解、アルカリ性加水分解、フッ化アンモニ
ウム処理、接触還元などの通常の処理を適宜選択して行
えばよい、たとえば、水酸基の保護基としてシリル基を
用いた場合には、フッ化アンモニウム処理、酸性もしく
はアルカリ性加水分解によりシリル基を除去することが
できる。The reaction for removing the protecting group from the hydroxyl group on the sugar moiety may be carried out by appropriately selecting a conventional treatment such as acidic hydrolysis, alkaline hydrolysis, ammonium fluoride treatment, or catalytic reduction depending on the protecting group used. When a silyl group is used as a protecting group, the silyl group can be removed by ammonium fluoride treatment or acidic or alkaline hydrolysis.
また、R3がリン酸残基である化合物は、オキシ塩化リ
ン、テトラクロロビロリン酸などの通常のヌクレオシド
の5″位の選択的リン酸化に使用するリン酸化剤と反応
させて得ることができる。In addition, compounds in which R3 is a phosphoric acid residue can be obtained by reacting with a phosphorylating agent used for selective phosphorylation of the 5'' position of ordinary nucleosides, such as phosphorus oxychloride and tetrachloropyrophosphoric acid. .
また、本発明の一般式(1)の化合物において、R1が
アミノである化合物は、塩基部4位の水酸基をアミノ基
に変換する通常のアミノ化反応に付すことにより取得す
ることができる。たとえば、上記方法により得られる糖
部3゛位、5°位の水酸基が保護された糖部2°位がメ
チリデンである化合物と1.2.4− トリアゾールと
をオキシ塩化リンおよびトリエチルアミンの存在下に反
応させて、4− (1,2,4−)リアゾール−1−イ
ル)体とし、ついでアンモニアガスを通じて4−アミノ
体とし、最後に前記と同様の方法により水酸基の保護基
除去反応を行ない、必要によりリン酸化することにより
得られる。Further, in the compound of the general formula (1) of the present invention, a compound in which R1 is amino can be obtained by subjecting the hydroxyl group at the 4-position of the base moiety to an ordinary amination reaction to convert it into an amino group. For example, a compound obtained by the above method in which the hydroxyl groups at the 3' and 5' positions of the sugar moiety are protected and the 2' position of the sugar moiety is methylidene and 1.2.4-triazole are mixed in the presence of phosphorus oxychloride and triethylamine. to form the 4-(1,2,4-)riazol-1-yl) form, then pass through ammonia gas to form the 4-amino form, and finally remove the protecting group from the hydroxyl group by the same method as above. , obtained by phosphorylation if necessary.
1.2.4−トリアゾールとの反応はアセトニトリルな
どの溶媒中、アルゴンなどの不活性ガス気流下にO″C
から室温付近、30分から5時間程度で進行する。アミ
ノ化反応に使用するアンモニアガスは水酸化ナトリウム
を予め通しておくとよい。アンモニアガスによるアミノ
化反応は通常1〜5時間程度行なうのがよい。1.2.The reaction with 4-triazole is carried out at O″C in a solvent such as acetonitrile under a stream of inert gas such as argon.
The process proceeds from about 30 minutes to 5 hours at room temperature. The ammonia gas used in the amination reaction is preferably passed through sodium hydroxide in advance. The amination reaction using ammonia gas is usually carried out for about 1 to 5 hours.
なお、本発明の出発原料として用いた一般式(■)の化
合物のうちRが炭素数2〜4個のアルキニルである化合
物は、たとえば次に示す方法によって製造することがで
きる。Among the compounds of general formula (■) used as starting materials in the present invention, compounds in which R is alkynyl having 2 to 4 carbon atoms can be produced, for example, by the method shown below.
(III) (IV) (
X’+(上記反応式中、R”はシリル保護された炭素数
2〜4個のアルキニルを、R″”は炭素数2〜4個のア
ルキニルを示す。)
上記反応は、化合物(I[l)とシリル保護されたアル
キニルの金属化合物とを反応させて化合物(■)を得て
、次いで脱シリル化することにより、目的の化合物(■
°)を得ることができる。(III) (IV) (
X'+ (In the above reaction formula, R'' represents a silyl-protected alkynyl having 2 to 4 carbon atoms, and R'' represents an alkynyl having 2 to 4 carbon atoms.) l) and a silyl-protected alkynyl metal compound to obtain the compound (■), which is then desilylated to obtain the desired compound (■
°) can be obtained.
また、さらに、−最大(n)の化合物のうち、Rが炭素
数2〜4個のアルキルである化合物は上記化合物(■°
)の糖部3゛位および5°位水酸基を上述の方法に従っ
て保護した後、還元反応に付し、その後、糖部3′位お
よび5゛位水酸基の保護基を除去することによって製造
することができる。但し、本発明の一般式(1)の化合
物のうちR2が炭素数2〜4個のアルキルである化合物
を製造する際には、上述の還元反応により得られる化合
物の糖部3゛位および5”位水酸基の保護基を除去する
ことなく、前述と同様の反応様式により糖部2゛位メチ
リデン体とし、その後、保護基を除去し、必要に応じ糖
部5°位水酸基をリン酸化すればよい。Furthermore, among the compounds with -maximum (n), the compounds in which R is alkyl having 2 to 4 carbon atoms are the above compounds (■°
) by protecting the hydroxyl groups at the 3′ and 5′ positions of the sugar moiety according to the method described above, subjecting it to a reduction reaction, and then removing the protecting groups for the hydroxyl groups at the 3′ and 5′ positions of the sugar moiety. Can be done. However, when producing a compound in which R2 is alkyl having 2 to 4 carbon atoms among the compounds of the general formula (1) of the present invention, the sugar moiety at the 3' position and the 5' position of the compound obtained by the above-mentioned reduction reaction is Without removing the protecting group for the hydroxyl group at the `` position, the methylidene form at the 2° position of the sugar moiety is obtained by the same reaction method as described above, and then the protecting group is removed, and if necessary, the hydroxyl group at the 5° position of the sugar moiety is phosphorylated. good.
本発明の目的化合物および合成中間体は通常の単離精製
法(たとえば、イオン交換、吸着などの各種クロマトグ
ラフィー法、再結晶法など)を適宜組合わせて単離精製
することができる。具体的には、たとえばヌクレオシド
体の場合溶媒を留去後、必要に応じカラムクロマトグラ
フィーに付し、適当な有機溶媒にて結晶化すればよく、
また、ヌクレオチド体(R’がリン酸残基)の場合には
イオン交換樹脂などのイオン交換カラムクロマトグラフ
ィー、活性炭などの吸着カラムクロマトグラフィーなど
により精製し、凍結乾燥または結晶化により遊離酸型を
得ることができ、必要に応じて塩型として得ることもで
きる。The target compounds and synthetic intermediates of the present invention can be isolated and purified by appropriately combining conventional isolation and purification methods (for example, various chromatography methods such as ion exchange and adsorption, recrystallization methods, etc.). Specifically, for example, in the case of a nucleoside, after distilling off the solvent, it may be subjected to column chromatography as necessary and crystallized with an appropriate organic solvent.
In the case of a nucleotide (R' is a phosphate residue), it is purified by ion exchange column chromatography using ion exchange resin, adsorption column chromatography using activated carbon, etc., and the free acid form is obtained by freeze-drying or crystallization. If necessary, it can also be obtained in the form of a salt.
このようにして得られる一般式(1)の化合物は常法に
より前記した酸付加塩、金属塩またはアンモニウム塩と
することができる。The compound of general formula (1) thus obtained can be converted into the above-mentioned acid addition salt, metal salt or ammonium salt by a conventional method.
本発明の化合物は、各種培養腫瘍細胞株に対し顕著な増
殖抑制効果を示し、かつ低毒性であることから、これら
を有効成分とする本発明医薬は制がん剤として有用であ
る0本発明の制がん剤は、有効量の化合物(1)と医薬
上許容しうる担体、賦形剤、希釈剤などと混合して、散
剤、顆粒、錠剤、糖衣錠、カプセル剤、シロンブ剤、坐
剤、外用剤、注射剤、点滴用剤などの形態をとり得る。Since the compounds of the present invention exhibit remarkable growth-inhibiting effects on various cultured tumor cell lines and have low toxicity, the pharmaceuticals of the present invention containing these as active ingredients are useful as anticancer agents. The anticancer agent can be prepared by mixing an effective amount of compound (1) with a pharmaceutically acceptable carrier, excipient, diluent, etc., and preparing it as a powder, granule, tablet, sugar-coated tablet, capsule, pill, or suppository. It can take the form of external preparations, injections, drip preparations, etc.
2゛−デオキシ−2°−メチリデンシチジンは、室温で
生理食塩水には25■/mi!の濃度で溶解しないのに
対して、実施例1の化合物(2°−デオキシ−2°−メ
チリデン−5−フルオロシチジン)は同様の条件下で5
溶である。2'-deoxy-2'-methylidenecytidine is 25 μ/mi in physiological saline at room temperature! The compound of Example 1 (2°-deoxy-2°-methylidene-5-fluorocytidine) did not dissolve under similar conditions.
It is melting.
本発明の制がん剤は、ヒトを含む哺乳動物に対し、経口
的または非経口的に投与されるが、特に経口投与が好ま
しい、投与量は、対象がんを有効に阻止する量であれば
よく、治療対象動物、がんの種類、投与経路、剤型など
により変動し得るが、一般に経口剤の場合、1日10〜
400■/kg体重、好ましくは50〜200■/kg
体重であり、注射剤では1日1〜20■/kg体重、好
ましくは1〜5■/kg体重である。投与回数は1日1
〜4回の範囲で適宜選択し得る。The anticancer agent of the present invention is administered orally or parenterally to mammals including humans, but oral administration is particularly preferable, and the dose may be any amount that effectively inhibits the target cancer. The dosage may vary depending on the animal to be treated, the type of cancer, the route of administration, the dosage form, etc., but in general, in the case of oral drugs, the dosage is 10 to 10 times a day.
400■/kg body weight, preferably 50-200■/kg
The body weight is 1 to 20 .mu./kg body weight, preferably 1 to 5 .mu./kg body weight per day for injections. The number of administrations is once a day.
The number of times can be selected as appropriate within the range of 4 times.
本発明の制がん剤は、他の制がん剤、免疫賦活剤または
その他の許容し得る薬剤などと併用することができる。The anticancer agent of the present invention can be used in combination with other anticancer agents, immunostimulants, or other acceptable drugs.
〔実施例]
以下、実施例により本発明を具体的に説明するが、本発
明はこれらに限定されるものではない。[Examples] Hereinafter, the present invention will be specifically explained with reference to Examples, but the present invention is not limited thereto.
実施例1
(1)5−フルオロウリジン2.62 gをピリジン3
0鵡Iに溶解し、0°Cで1. 3−ジクロロ−1,1
,3,3−テトライソプロピルジシロキサン3.31を
加え2時間、室温に戻して1.5時間撹拌した。水を5
1加え、溶媒を減圧留去した。酢酸エチル100−1、
水1001を加え、分液し、有機層を2回水洗後硫酸ナ
トリウムで乾燥し、溶媒を減圧留去した。残香をシリカ
ゲルカラム(φ2.4X23cm)で分取した。25%
酢酸エチル/ヘキサンで溶出すると、3’、5’−0−
テトライソプロビルジシロキサニル−5−フルオロウリ
ジンをあめ状物質として得た。収量4.24g、収率8
3.9%。Example 1 (1) 2.62 g of 5-fluorouridine was mixed with 3 g of pyridine.
1. 3-dichloro-1,1
, 3,3-tetraisopropyldisiloxane was added thereto for 2 hours, and the mixture was returned to room temperature and stirred for 1.5 hours. 5 liters of water
1 was added, and the solvent was distilled off under reduced pressure. ethyl acetate 100-1,
1,001 liters of water was added, the layers were separated, and the organic layer was washed twice with water, dried over sodium sulfate, and the solvent was distilled off under reduced pressure. The residual fragrance was collected using a silica gel column (φ2.4×23 cm). 25%
Elution with ethyl acetate/hexane yields 3',5'-0-
Tetraisoprobyldisiloxanyl-5-fluorouridine was obtained as a candy-like substance. Yield 4.24g, yield 8
3.9%.
Mass (II/Z): 504 (M”)、 46
1 (M”−イソプロピル)(2) (+)で得られ
た化合物5gを塩化メチレンl〇−1に溶解し、4当量
のクロム酸コンプレックス(塩化メチレン1001中酸
化クロム4g、ピリジン6.67m1.無水酢酸4−1
)に混合し、室温で1時間撹拌した。酢酸エチル500
elに滴下し、φ6、OXl、5C11のシリカゲルで
濾過した。濾液を減圧留去し、残香を酢酸エチル200
sIl、水200m1で分液した。有機層を水洗後、硫
酸ナトリウムで乾燥し、溶媒を減圧留去、残香をシリカ
ゲルカラム(φ2.4X2BC1m)で分取し、20%
酢酸エチル/ヘキサンで溶出し、ヘキサンから結晶化し
て、3”、5”−〇−テトライソプロビルジシロキサニ
ル−2°−オキソ−5−フルオロウリジンを得た。Mass (II/Z): 504 (M”), 46
1 (M"-isopropyl) (2) (+) 5 g of the compound obtained in 10-1 methylene chloride was dissolved, and 4 equivalents of chromic acid complex (4 g of chromium oxide in 1001 methylene chloride, 6.67 ml of pyridine. Acetic anhydride 4-1
) and stirred at room temperature for 1 hour. ethyl acetate 500
el, and filtered through φ6, OXl, 5C11 silica gel. The filtrate was distilled off under reduced pressure, and the residual aroma was dissolved in ethyl acetate.
The liquid was separated with sIl and 200 ml of water. After washing the organic layer with water, it was dried over sodium sulfate, the solvent was distilled off under reduced pressure, and the residual aroma was collected using a silica gel column (φ2.4 x 2 BC 1 m) to give 20%
Elution with ethyl acetate/hexane and crystallization from hexane gave 3",5"-〇-tetraisoprobyl disiloxanyl-2°-oxo-5-fluorouridine.
収14.3g、収率86%、融点183〜186℃。Yield: 14.3 g, yield: 86%, melting point: 183-186°C.
Mass (m/z): 502 (M・)。Mass (m/z): 502 (M.).
元素分析値 Cz+H3sNzOyFS izとシテ:
計算値: C: 50.17 H; 7.02 N
; 5.57実測(!! : C、50,29H、7
,33N 、 5.58(3)テトラヒドロフラン80
nl中、アルゴン気流下臭化メチルトリフェニルホスホ
ニウム8.57 gを懸濁し、0°Cでn−ブチルリチ
ウム(]、58mol/l、ヘキサン溶液)15.1m
lを滴下し、室温に戻し1時間撹拌した。(2)で得ら
れた化合物3.02 gのテトラヒドロフラン25m1
溶液をアルゴン気流下0°Cで滴下した。20分後室温
に戻し、3時間撹拌した。IN臭化アンモニウムで中和
し、溶液を濃縮した。酢酸エチル1ocal、水100
m1を加え分液し、有機層を水洗後硫酸ナトリウムで乾
燥し、減圧留去した。残香をシリカゲルカラム(φ3.
5X1Bcm)で分取し、20%酢酸エチル/ヘキサン
で溶出すると、3’、5’−0−テトライソプロビルジ
シロキサニル−2゛−デオキシ−2゛−メチリチン−5
−フルオロウリジンを、あめ状物質として得た。収量2
.43g、収率81%、 Mass (m/z):50
0 (M”) 。Elemental analysis value Cz+H3sNzOyFS iz and shite:
Calculated value: C: 50.17 H; 7.02 N
; 5.57 actual measurement (!!: C, 50, 29H, 7
, 33N, 5.58 (3) Tetrahydrofuran 80
8.57 g of methyltriphenylphosphonium bromide was suspended in nl under an argon atmosphere, and 15.1 m of n-butyllithium (], 58 mol/l, hexane solution) was suspended at 0°C.
1 was added dropwise, the temperature was returned to room temperature, and the mixture was stirred for 1 hour. 3.02 g of the compound obtained in (2) and 25 ml of tetrahydrofuran
The solution was added dropwise at 0°C under an argon stream. After 20 minutes, the mixture was returned to room temperature and stirred for 3 hours. Neutralized with IN ammonium bromide and concentrated the solution. ethyl acetate 1ocal, water 100%
The organic layer was washed with water, dried over sodium sulfate, and evaporated under reduced pressure. The residual fragrance was removed through a silica gel column (φ3.
5 x 1 Bcm) and eluted with 20% ethyl acetate/hexane to give 3',5'-0-tetraisoprobyl disiloxanyl-2'-deoxy-2'-methylitin-5.
-Fluorouridine was obtained as a candy-like substance. Yield 2
.. 43g, yield 81%, Mass (m/z): 50
0 (M”).
(4)アセトニトリル101にトリエチルアミン1.4
ml、 1.2.4− トリアゾール684■を熔解し
、アルゴン気流下θ℃に冷却した。オキシ塩化リン28
02aを滴下し室温に戻し、1時間撹拌した。沈澱を濾
去し、濾液に(3)の化合物500■のアセトニトリル
5ml溶液を滴下した。室温3時間後、50°Cで1時
間撹拌し、水酸化ナトリウムを通したアンモニアガスを
4時間通じた。クロロホルム100−1、水1ocal
を加え、分液し、水層をクロロホルムで2回洗い、クロ
ロホルム層をまとめて、硫酸ナトリウムで乾燥し減圧留
去した。残香をシリカゲルカラム(φ3.5X14c+
a)で分取し、5%エタノール/クロロホルムで溶出す
ると、3”、5′−0−テトライソプロビルジシロキサ
ニル−2゛−デオキシ−2゛−メチリデン−5−フルオ
ロシチジンをあめ状物質として得た。収量435■、収
率87%、 Mass (m/z)= 499
(11”) 。(4) 1.4 parts triethylamine to 10 parts acetonitrile
684 ml of 1.2.4-triazole was melted and cooled to θ°C under an argon stream. Phosphorus oxychloride 28
02a was added dropwise, the temperature was returned to room temperature, and the mixture was stirred for 1 hour. The precipitate was filtered off, and a solution of 500 μl of compound (3) in 5 ml of acetonitrile was added dropwise to the filtrate. After 3 hours at room temperature, the mixture was stirred at 50°C for 1 hour, and ammonia gas passed through sodium hydroxide was passed through the mixture for 4 hours. Chloroform 100-1, water 1ocal
The aqueous layer was washed twice with chloroform, the chloroform layers were combined, dried over sodium sulfate, and evaporated under reduced pressure. Remove the residual fragrance using a silica gel column (φ3.5X14c+
When fractionated in step a) and eluted with 5% ethanol/chloroform, 3'',5'-0-tetraisoprobyldisiloxanyl-2'-deoxy-2'-methylidene-5-fluorocytidine was obtained as a candy-like substance. Yield: 435 cm, yield: 87%, Mass (m/z) = 499
(11”).
(5) (4)で得た化合物4001Igをテトラヒ
ドロフラン10m1に熔解し、・フッ化テトラ−n−ブ
チルアンモニウム1.8mlを加え、室温で30分撹拌
した。(5) Compound 4001Ig obtained in (4) was dissolved in 10 ml of tetrahydrofuran, 1.8 ml of tetra-n-butylammonium fluoride was added, and the mixture was stirred at room temperature for 30 minutes.
酢酸で中和し、溶媒を減圧留去した。残香をシリカゲル
カラム(φ2.4X18c■)で分取し、エタノール/
クロロホルムで溶出し、エタノール−酢酸エチルから結
晶化すると、2′−デオキシ−2゜−メチリデン−5−
フルオロシチジンを得た。収1it177m、収率86
.2%、融点185〜187’C,Mass (m/z
): 25701”) 。The mixture was neutralized with acetic acid, and the solvent was distilled off under reduced pressure. The residual fragrance was collected using a silica gel column (φ2.4×18c), and ethanol/
Elution with chloroform and crystallization from ethanol-ethyl acetate yielded 2'-deoxy-2°-methylidene-5-
Fluorocytidine was obtained. Yield 1 it 177 m, yield 86
.. 2%, melting point 185-187'C, Mass (m/z
): 25701”).
元素分析値 C1゜H1x N ’x O4Fとして:
計算値: C、46,70H; 4.70 N i
16.34実測値: C; 46.06 II
; 4.67 N i 16.00実施例2
(1) アセトニトリル10m1にトリエチルアミン
1.4−1.1,2.4−トリアゾール684■を溶解
し、アルゴン気流下O℃に冷却した。オキシ塩化リン2
80μを滴下し、室温に戻し、1時間撹拌した。沈澱を
濾去し、濾液にチミジンから実施例1 (1)〜(3)
のようにして得た3°、5’−0−テトライソプロビル
ジシロキサニル−2°−デオキシ−2′−メチリデンチ
ミジン、498■のア七ト二トリル5−1溶液を滴下し
た。3時間後、水酸化ナトリウムを通したアンモニアガ
スを通じた。3時間後、クロロホルム1001、水10
0m1を加え分液し、水層をクロロホルムで2回洗い、
クロロホルム層を集めて、硫酸ナトリウムで乾燥後、減
圧留去した。残香をシリカゲルカラム(φ3,5X12
C1)で分取し、5%エタノール/クロロホルムで溶出
すると、3°。Elemental analysis value as C1゜H1x N'x O4F:
Calculated value: C, 46,70H; 4.70 N i
16.34 Actual value: C; 46.06 II
; 4.67 N i 16.00 Example 2 (1) 684 μ of triethylamine 1.4-1.1,2.4-triazole was dissolved in 10 ml of acetonitrile and cooled to 0° C. under an argon stream. Phosphorus oxychloride 2
80μ was added dropwise, the temperature was returned to room temperature, and the mixture was stirred for 1 hour. The precipitate was filtered off, and the filtrate was mixed with thymidine from Example 1 (1) to (3).
A solution of 498 ml of 3°,5'-0-tetraisopropyldisiloxanyl-2°-deoxy-2'-methylidenethymidine obtained as above in a7tonitrile 5-1 was added dropwise. After 3 hours, ammonia gas was passed through sodium hydroxide. After 3 hours, 100 parts of chloroform, 10 parts of water
Add 0ml and separate the layers, wash the aqueous layer twice with chloroform,
The chloroform layer was collected, dried over sodium sulfate, and then evaporated under reduced pressure. Remove the residual fragrance using a silica gel column (φ3, 5×12
C1) and eluted with 5% ethanol/chloroform at 3°.
5゛−0−テトライソプロビルジシロキサニル−2゛−
デオキシ−2゛−メチリデン−5−メチルシチジンを、
あめ状物質として得た。収量315■、収率63.3
%、 Mass (m/z): 495 (M
”) 。5゛-0-tetraisopropyldisiloxanyl-2゛-
Deoxy-2゛-methylidene-5-methylcytidine,
Obtained as a candy-like substance. Yield 315■, Yield 63.3
%, Mass (m/z): 495 (M
”).
(2) (1)で得た化合物300■をテトラヒドロ
フラン10m1に溶解し、フン化テトラ−n−ブチルア
ンモニウム1.4mlを加え、室温で30分撹拌した。(2) 300 ml of the compound obtained in (1) was dissolved in 10 ml of tetrahydrofuran, 1.4 ml of tetra-n-butylammonium fluoride was added, and the mixture was stirred at room temperature for 30 minutes.
酢酸で中和し溶媒を減圧留去し、残香をシリカゲルカラ
ム(φ2.4X17c重)で分取し、エタノール/クロ
ロホルムで溶出し、エタノール−酢酸エチルから結晶化
して、2゛−デオキシ−2゛−メチリデン−5−メチル
シチジンを得た。収ff1137■、収率89.θ%、
融点198〜204°C(分解)。Neutralize with acetic acid, remove the solvent under reduced pressure, collect the residual aroma using a silica gel column (φ2.4×17c weight), elute with ethanol/chloroform, crystallize from ethanol-ethyl acetate, and obtain 2゛-deoxy-2゛. -Methylidene-5-methylcytidine was obtained. Yield ff1137■, yield 89. θ%,
Melting point 198-204°C (decomposition).
Mass (+s/z)= 253 (M”) 。Mass (+s/z) = 253 (M”).
元素分析値 C+ + H+ s N 、Oaとして:
計算値: Ci 52.17 Hi 5.97
N ; 16.59実測値: Ci 52.02
H、5,99N ; 16.37実施例3
(1)5−クロロウリジンlOgをピリジン100−1
に溶解し、0℃で1,3−ジクロロ−1,1,3,3−
テトライソプロピルジシロキサン12.44N+を加え
、3時間撹拌した。室温に戻し2時間攪拌後、エタノー
ル5ml加え、溶媒を減圧留去した。残香を酢酸エチル
200m1、水2001で分液後有機層を硫酸ナトリウ
ムで乾燥、減圧留去し、残香をシリカゲルカラム(φ3
.OX25cm)で分取し、25%酢酸エチル/ヘキサ
ンで溶出すると、あめ状物質として、3’、5’−0−
テトライソプロビルジシロキサニル−5−クロロウリジ
ンを得た。収量14.63 g 、収率78.2%。M
ass (m/z): 47B (M’−イソプロピル
)。Elemental analysis value C+ + H+ s N, as Oa:
Calculated values: Ci 52.17 Hi 5.97
N; 16.59 Actual value: Ci 52.02
H, 5,99N; 16.37 Example 3 (1) 1Og of 5-chlorouridine to 100-1 of pyridine
1,3-dichloro-1,1,3,3-
12.44N+ of tetraisopropyldisiloxane was added and stirred for 3 hours. After returning to room temperature and stirring for 2 hours, 5 ml of ethanol was added and the solvent was distilled off under reduced pressure. After separating the residual aroma with 200ml of ethyl acetate and 200ml of water, the organic layer was dried over sodium sulfate, distilled off under reduced pressure, and the residual aroma was transferred to a silica gel column (φ3
.. OX25cm) and eluted with 25% ethyl acetate/hexane, 3',5'-0-
Tetraisopropyldisiloxanyl-5-chlorouridine was obtained. Yield 14.63 g, yield 78.2%. M
ass (m/z): 47B (M'-isopropyl).
(2) (1)で得た化合物5.21gを塩化メチレ
ン15−Iに熔解し、4当量のクロム酸コンプレックス
(塩化メチレン100+Ill中に酸化クロム4g、ピ
リジン5.0+1.無水酢酸4+al)に混合し、2時
間撹拌した0反応液を酢酸エチル4001に滴下し、φ
6. OX 1. Ocmのシリカゲルで濾過した。溶
媒を減圧留去し、残金をシリカゲルカラム(φ2.4×
30c+a)で分取し、25%酢酸エチル/ヘキサンで
溶出し、酢酸エチル/ヘキサンから結晶化して、3”。(2) Dissolve 5.21 g of the compound obtained in (1) in methylene chloride 15-I and mix with 4 equivalents of chromic acid complex (chromium oxide 4 g, pyridine 5.0 + 1. acetic anhydride 4 + al in methylene chloride 100 + Ill). Then, the 0 reaction solution stirred for 2 hours was added dropwise to ethyl acetate 4001, and φ
6. OX 1. Filtered through Ocm silica gel. The solvent was distilled off under reduced pressure, and the residue was transferred to a silica gel column (φ2.4×
30c+a), eluted with 25% ethyl acetate/hexane, and crystallized from ethyl acetate/hexane to yield 3".
5″−O−テトライソプロビルジシロキサニル−2゛−
オキソ−5−クロロウリジンを得た。収量3.75g、
収率72%。融点199〜201″C,Mass (I
S/Z)F476 (M”−イソプロピル)。5″-O-tetraisopropyldisiloxanyl-2″-
Oxo-5-chlorouridine was obtained. Yield 3.75g,
Yield 72%. Melting point 199~201″C, Mass (I
S/Z) F476 (M”-isopropyl).
元素分析値 CzrH2sNzOtCIS ilとして
二計算値: Ci 4B、49 H: 6.78 N
; 5.39実測値: Ci 48.24 Hi
7.02 N 、 5.18(3)臭化メチルトリ
フェニルホスホニウム5.72gをテトラヒドロフラン
50*Lにアルゴン気流下懸濁し、水冷下n−ブチルリ
チウム10.1mlを滴下した。室温に戻し、1時間撹
拌後、0°Cに冷却し、(2)で得た化合物2.08
gのテトラヒドロフラン10m1溶液を滴下し、30分
後室温に戻した。Elemental analysis value CzrH2sNzOtCIS Two calculated values as il: Ci 4B, 49 H: 6.78 N
; 5.39 Actual value: Ci 48.24 Hi
7.02 N, 5.18(3) 5.72 g of methyltriphenylphosphonium bromide was suspended in 50*L of tetrahydrofuran under an argon stream, and 10.1 ml of n-butyllithium was added dropwise under water cooling. Returned to room temperature, stirred for 1 hour, cooled to 0°C, and obtained compound 2.08 obtained in (2).
A solution of 10 g in 10 ml of tetrahydrofuran was added dropwise thereto, and after 30 minutes the temperature was returned to room temperature.
5時間後、IN臭化アンモニウムで中和し、酢酸エチル
100m1、水100s+1を加え、分液した。After 5 hours, the mixture was neutralized with IN ammonium bromide, and 100 ml of ethyl acetate and 100 s+1 of water were added to separate the layers.
有機層を水洗後、硫酸ナトリウムで乾燥し、減圧留去し
た。残金をシリカゲルカラム(φ5.0X14C+a)
で分取し、25%酢酸エチル/ヘキサンで溶出すると、
あわ状物質として、3゛、5°−0−テトライソプロビ
ルジシロキサニル−2°−デオキシ−2゜−メチリデン
−5−クロロウリジンを得た。収量1.7g、収率81
.7%。Mass (m/z): 517 (M”)。The organic layer was washed with water, dried over sodium sulfate, and evaporated under reduced pressure. Transfer the remaining amount to a silica gel column (φ5.0X14C+a)
When fractionated and eluted with 25% ethyl acetate/hexane,
3',5'-0-tetraisopropyldisiloxanyl-2'-deoxy-2'-methylidene-5-chlorouridine was obtained as a foamy substance. Yield 1.7g, Yield 81
.. 7%. Mass (m/z): 517 (M”).
(4)アセトニトリル201中、アルゴン気流下トリエ
チルアミン3mlと1.2.4− トリアゾール1.5
2gを溶解し、氷冷した。オキシ塩化リン6204を滴
下し、30分後室温に戻して30分間撹拌した。沈澱を
濾去し、濾液に(3)で得た化合物1.04gを加え、
室温で3時間撹拌した。水酸化ナトリウムを通したアン
モニアガスを2時間通じ、クロロホルム100m1、水
100m1を加えて分液した。(4) 3 ml of triethylamine and 1.5 ml of 1.2.4-triazole in 20 ml of acetonitrile under a stream of argon.
2g was dissolved and cooled on ice. Phosphorus oxychloride 6204 was added dropwise, and after 30 minutes, the mixture was returned to room temperature and stirred for 30 minutes. The precipitate was filtered off, and 1.04 g of the compound obtained in (3) was added to the filtrate.
Stirred at room temperature for 3 hours. Ammonia gas was passed through sodium hydroxide for 2 hours, and 100 ml of chloroform and 100 ml of water were added to separate the layers.
水層をクロロホルムで洗い、クロロホルム層を集めて、
硫酸ナトリウムで乾燥後、減圧留去した。Wash the aqueous layer with chloroform, collect the chloroform layer,
After drying with sodium sulfate, the residue was distilled off under reduced pressure.
残金をシリカゲルカラム(φ3.5X17cm)t”分
取し、75%酢酸エチル/ヘキサンで溶出し、酢酸エチ
ルから結晶化すると、3″、5°−O−テトライソプロ
とルジシロキサニルー2°−デオキシ−2°−メチリデ
ン−5−クロロシチジンを得た。収量944■、収率9
0,7%、融点108〜111 ’C,Mass(w+
/z) : 517 (M”)。The residue was collected using a silica gel column (φ3.5 x 17 cm), eluted with 75% ethyl acetate/hexane, and crystallized from ethyl acetate to yield 3", 5°-O-tetraisopro and 2°- Deoxy-2°-methylidene-5-chlorocytidine was obtained. Yield 944■, yield 9
0.7%, melting point 108-111'C, Mass (w+
/z): 517 (M”).
(5) (4)で得た化合物900■をテトラヒドロ
フラン10m1に溶解し、フッ化テトラーn−ブチルア
ンモニウム4+slを加え、室温で30分間撹拌した。(5) 900 μl of the compound obtained in (4) was dissolved in 10 ml of tetrahydrofuran, 4+sl of tetra-n-butylammonium fluoride was added, and the mixture was stirred at room temperature for 30 minutes.
メタノール5mlを加え、溶媒を減圧留去し、残金をシ
リカゲルカラム(φ3.5 X 12cm)で分取し、
20%エタノール/クロロホルムで溶出し、エタノール
−酢酸エチルから結晶化して、2゛−デオキシ−2−メ
チリデン−5−クロロシチジンを得た。Add 5 ml of methanol, evaporate the solvent under reduced pressure, and collect the residue using a silica gel column (φ3.5 x 12 cm).
Elution with 20% ethanol/chloroform and crystallization from ethanol-ethyl acetate gave 2'-deoxy-2-methylidene-5-chlorocytidine.
収fi441■、収率93.4%、融点168〜170
°C。Yield fi441■, yield 93.4%, melting point 168-170
°C.
Mass (s/z): 273 (M”)
。Mass (s/z): 273 (M”)
.
実施例4
(1)5−ブロモウリジン3.32 gをピリジン30
m1に溶解し、O″Cで1.3−ジクロロ−1,1,3
,3−テトライソプロピルジシロキサン3.31を加え
、2時間撹拌した。更に室温に戻して1時間40分撹拌
した。水を51加え、溶媒を減圧留去した。Example 4 (1) 3.32 g of 5-bromouridine was mixed with 30 g of pyridine.
1,3-dichloro-1,1,3 dissolved in O″C
, 3-tetraisopropyldisiloxane were added thereto, and the mixture was stirred for 2 hours. The mixture was further returned to room temperature and stirred for 1 hour and 40 minutes. 51 g of water was added and the solvent was distilled off under reduced pressure.
エタノール共沸後、残金をシリカゲルカラム(φ2.4
X25cm)で分取し、25%酢酸エチル/ヘキサンで
溶出すると、あめ状物質として3゛、5“、〇−テトラ
イソプロビルジシロキサニル−5−ブロモウリジンを得
た。収、If5.05g、収率89.2%。After ethanol azeotropy, the remaining residue was transferred to a silica gel column (φ2.4
25 cm) and eluted with 25% ethyl acetate/hexane to obtain 3', 5', 0-tetraisoprobyl disiloxanyl-5-bromouridine as a candy-like substance. Yield, If 5.05 g, Yield 89.2%.
Maaa (m/z): 522 (M”−イソプロピ
ル)。Maaa (m/z): 522 (M''-isopropyl).
(2) (1)で得た化合物3.57gを4当量のク
ロム酸コンプレックス(塩化メチレン701中、酸化ク
ロム2.4g、ピリジン4!Il、無水酢酸2.4+a
l)に混合し、室温で40分間撹拌した。反応液を酢酸
エチル4001 に滴下し、φ6. OX 1. Oc
mのシリカゲルで濾過した。濾液を濃縮し、酢酸エチル
150m1、水150m1を加え、分液した。有機層を
水洗後、硫酸ナトリウムで乾燥し、溶媒を減圧留去した
。残金をシリカゲルカラム(φ5.0X14C1)で分
取し、20%酢酸エチル/ヘキサンで溶出し、酢酸エチ
ル−ヘキサンから結晶化して、3°、5’−0−テトラ
イソプロビルジシロキサニル−2゛−オキソ−5−ブロ
モウリジンを得た。収13.01g、収率84.8%、
融点204〜205°C,Mass (g+/z):5
20 (M’−イソプロピル)。(2) Add 3.57 g of the compound obtained in (1) to 4 equivalents of a chromic acid complex (2.4 g of chromium oxide, 4 Il of pyridine, 2.4 + acetic anhydride in 701 methylene chloride)
1) and stirred at room temperature for 40 minutes. The reaction solution was added dropwise to ethyl acetate 4001, and the solution was added to φ6. OX 1. Oc
The mixture was filtered through silica gel. The filtrate was concentrated, 150 ml of ethyl acetate and 150 ml of water were added, and the layers were separated. The organic layer was washed with water, dried over sodium sulfate, and the solvent was distilled off under reduced pressure. The residue was collected using a silica gel column (φ5.0×14C1), eluted with 20% ethyl acetate/hexane, and crystallized from ethyl acetate/hexane to give 3°, 5′-0-tetraisopropyldisiloxanyl-2′. -Oxo-5-bromouridine was obtained. Yield 13.01g, yield 84.8%,
Melting point 204-205°C, Mass (g+/z): 5
20 (M'-isopropyl).
元素分析値 C*+H3sNzOtS 1tBrとして
:計算値: C; 44.75 H; 6.26 N
i 4.97実測値: C; 44.57 Hi
6.32 N ? 4.92(3) 臭化メチルト
リフェニルホスホニウム5.72gをテトラヒドロフラ
ン50m1中にアルゴン気流下懸濁し、0℃でn−ブチ
ルリチウム10.1+*lを滴下する。室温に戻し、1
時間後、(2)で得た化合物2.25 gのテトラヒド
ロフラン15蒙l溶液を0“Cで滴下した。3時間後室
温に戻し、−晩撹拌し、IN臭化アンモニウムで中和し
、酢酸エチル150m1.水1501を加え、分液した
。酢酸エチル層を水洗後、硫酸ナトリウムで乾燥し、溶
媒を減圧留去した。残金をシリカゲルカラム(φ5.0
X14C■)で分取し、25%酢酸エチル/ヘキサンで
溶出すると、あわ状物質として3’、5’−0−テトラ
イソプロビルジシロキサニル−2゛−デオキシ−2゛−
メチリデン−5−ブロモウリジンを得た。収量1.72
g1収率76.4%、 Mass (s/z): 51
B (M”−イソプロピル)。Elemental analysis value C*+H3sNzOtS As 1tBr: Calculated value: C; 44.75 H; 6.26 N
i 4.97 Actual value: C; 44.57 Hi
6.32 N? 4.92(3) 5.72 g of methyltriphenylphosphonium bromide are suspended in 50 ml of tetrahydrofuran under a stream of argon, and 10.1+*l of n-butyllithium are added dropwise at 0°C. Return to room temperature, 1
After an hour, a solution of 2.25 g of the compound obtained in (2) in 15 mol of tetrahydrofuran was added dropwise at 0"C. After 3 hours, the temperature was returned to room temperature, stirred overnight, neutralized with IN ammonium bromide, and acetic acid. 150ml of ethyl.150ml of water was added and the layers were separated.The ethyl acetate layer was washed with water, dried over sodium sulfate, and the solvent was distilled off under reduced pressure.The residue was collected using a silica gel column (φ5.0
X14C■) and eluted with 25% ethyl acetate/hexane, 3',5'-0-tetraisopropyldisiloxanyl-2'-deoxy-2'-
Methylidene-5-bromouridine was obtained. Yield 1.72
g1 yield 76.4%, Mass (s/z): 51
B (M”-isopropyl).
(4) アセトニトリル20w1中、アルゴン気流下
トリエチルアミン31と1.2.4−トリアゾール】、
52gを溶解し、氷冷した。オキシ塩化リン620P4
を滴下し、30分後室温に戻して30分抜法澱を濾去し
、濾液に(3)で得た化合物1.12gを加え、室温で
3時間撹拌した。水酸化ナトリウムを通したアンモニア
ガスを3時間通じ、クロロホルム1001、水1001
を加えて分液した。水層をクロロホルムで洗い、クロロ
ホルム層を集めて、硫酸ナトリウムで乾燥し、溶媒を減
圧留去した。残金をシリカゲルカラム(φ3.5X17
.)で分取し、75%酢酸エチル/ヘキサンで溶出し、
酢酸エチルヘキサンから結晶化すると3°、5’−0−
テトライソプロビルジシロキサニル−2°−デオキシ−
2°−メチリデン−5−ブロモシチジンを得た。収量9
26■、収率82.7%、融点169〜17F(、Ma
ss(II/Z): 560 (M ”) 。(4) Triethylamine 31 and 1,2,4-triazole in 20w1 acetonitrile under a stream of argon],
52g was dissolved and cooled on ice. Phosphorus oxychloride 620P4
was added dropwise, and after 30 minutes, the temperature was returned to room temperature, and the precipitate was removed by filtration. 1.12 g of the compound obtained in (3) was added to the filtrate, and the mixture was stirred at room temperature for 3 hours. Passing ammonia gas through sodium hydroxide for 3 hours, chloroform 1001, water 1001
was added and separated. The aqueous layer was washed with chloroform, the chloroform layer was collected, dried over sodium sulfate, and the solvent was distilled off under reduced pressure. Transfer the remaining amount to a silica gel column (φ3.5×17
.. ) and eluted with 75% ethyl acetate/hexane.
Crystallization from ethyl acetate hexane gives 3°, 5'-0-
Tetraisoprobyl disiloxanyl-2°-deoxy-
2°-methylidene-5-bromocytidine was obtained. Yield 9
26■, yield 82.7%, melting point 169-17F (, Ma
ss(II/Z): 560 (M'').
(5) (4)で得た化合物900■をテトラヒドロ
フラン10m1に溶解し、フッ化テトラ−n−ブチルア
ンモニウム41を加え、室温で30分間撹拌した。(5) 900 ml of the compound obtained in (4) was dissolved in 10 ml of tetrahydrofuran, 41 ml of tetra-n-butylammonium fluoride was added, and the mixture was stirred at room temperature for 30 minutes.
メタノール51を加え、減圧留去した。残金をシリカゲ
ルカラム(φ3.5X11cm)で分取し、20%エタ
ノール/クロロホルムで溶出し、エタノール−酢酸エチ
ルから結晶化し、2°−デオキシ−2°−メチリデン−
5−ブロモシチジンを得た。51 ml of methanol was added and evaporated under reduced pressure. The residue was collected using a silica gel column (φ3.5×11 cm), eluted with 20% ethanol/chloroform, and crystallized from ethanol-ethyl acetate to give 2°-deoxy-2°-methylidene-
5-bromocytidine was obtained.
518■、収率102%、融点172〜180℃(分解
) 、 Mass (II/Z): 318 (Mつ。518■, yield 102%, melting point 172-180°C (decomposition), Mass (II/Z): 318 (M).
実施例5
(1)5−ヨウドウリジン10gをピリジン100鶴1
に溶解し、1.3−ジクロロ−1,1,3,3−テトラ
イソプロピルジシロキサン8.91を0℃で加え、1、
5時間撹拌した。室温に戻して3時間抜水10m1加え
、溶媒を減圧留去した。エタノール共沸後、残金をシリ
カゲルカラム(φ3.OX30cm)で分取し、25%
酢酸エチル/ヘキサンで溶出すると、あめ状物質として
3°、5″−0−テトライソプロビルジシロキサニル−
5−ヨウドウリジンを得た。収ffi 14.7 g、
収率89%0Mass (m/z): 612 (M”
)。Example 5 (1) 10 g of 5-iodouridine to 100 pyridine 1
8.91 of 1,3-dichloro-1,1,3,3-tetraisopropyldisiloxane was added at 0°C, and 1.
Stirred for 5 hours. The temperature was returned to room temperature, 10 ml of water was added for 3 hours, and the solvent was distilled off under reduced pressure. After ethanol azeotropy, the residue was fractionated using a silica gel column (φ3.OX30cm) and 25%
Elution with ethyl acetate/hexane yields 3°, 5″-0-tetraisoprobyl disiloxanyl- as a syrupy substance.
5-iodouridine was obtained. Yield 14.7 g,
Yield 89% 0Mass (m/z): 612 (M”
).
(2) (1)で得た化合物5.62 gを4当量の
クロム酸コンプレックス(塩化メチレン1001中、酸
化クロム3.55g、ピリジン5.91、無水酢酸3.
551)に混合し、室温で40分間撹拌した。反応液を
酢酸エチル500s+lに滴下し、φ6.0X15C1
のシリカゲルで濾過した濾液を減圧留去した。残金をシ
リカゲルカラム(φ5.OX21cm)で分取し、25
%酢酸エチル/ヘキサンで溶出して、3゛。(2) 5.62 g of the compound obtained in (1) was mixed with 4 equivalents of chromic acid complex (3.55 g of chromium oxide, 5.91 g of pyridine, 3.1 g of acetic anhydride in 100 l of methylene chloride).
551) and stirred at room temperature for 40 minutes. The reaction solution was added dropwise to 500 s+l of ethyl acetate, and φ6.0×15C1
The filtrate filtered through silica gel was distilled off under reduced pressure. The remaining amount was collected using a silica gel column (φ5.OX21cm), and 25
Elute with 3% ethyl acetate/hexane.
5′−0−テトライソプロビルジシロキサニル−21−
オキソ−5−ヨウドウリジンを得た。収量1.72g、
収率76.4%、 Mass (+*/z): 610
(M’)。5'-0-tetraisopropyldisiloxanyl-21-
Oxo-5-iodouridine was obtained. Yield 1.72g,
Yield 76.4%, Mass (++/z): 610
(M').
(3)臭化メチルトリフェニルホスホニウム7.94g
をテトラヒドロフラン801にアルゴン気流下懸濁し、
0℃でn−ブチルリチウム141を滴下した。室温に戻
し1時間後、O′Cに冷却し、(2)で得た化合物3.
39 gのテトラヒドロフラン151溶液を滴下した。(3) Methyltriphenylphosphonium bromide 7.94g
suspended in tetrahydrofuran 801 under a stream of argon,
At 0°C, n-butyllithium 141 was added dropwise. After returning to room temperature for 1 hour, cooling to O'C, compound 3. obtained in (2).
39 g of tetrahydrofuran 151 solution was added dropwise.
1時間後室温に戻し、−晩撹拌した。IN臭化アンモニ
ウムで中和し、am後、酢酸エチル200m1、水2Q
Omlを加え、分液した。有機層を硫酸ナトリウムで乾
燥し、減圧留去した。残香をシリカゲルカラム(φ5.
0X22c+*)で分取し、20%酢酸エチル/ヘキサ
ンで溶出すると、3’、5’−0−テトライソプロビル
ジシロキサニル−2′−デオキシ−2°−メチリデン−
5−ヨウドウリジンをあめ状物質として得た。収11.
6g、収率47.2%、 Mass (It/Z):
608 (M’) 。After 1 hour, the mixture was returned to room temperature and stirred overnight. Neutralize with IN ammonium bromide and add 200ml of ethyl acetate, 2Q of water
Oml was added and the liquid was separated. The organic layer was dried over sodium sulfate and evaporated under reduced pressure. The residual fragrance was removed through a silica gel column (φ5.
0X22c+*) and eluted with 20% ethyl acetate/hexane to give 3',5'-0-tetraisoprobyldisiloxanyl-2'-deoxy-2°-methylidene-
5-iodouridine was obtained as a candy-like substance. Collection 11.
6g, yield 47.2%, Mass (It/Z):
608 (M').
(4)アセトニトリル10m1中、アルゴン気流下トリ
エチルアミン1.51と1.2.4− )リアゾール7
60■を溶解し、氷冷した。オキシ塩化リン310#&
を滴下し、30分後室温に戻し、30分抜法澱を濾去し
、濾液に(3)で得た化合物321■を加え、室温で3
時間撹拌した。水酸化ナトリウムを通したアンモニアガ
スを3時間通じ、クロロホルム50a1、水501を加
えて分液した。水層をクロロホルムで洗い、有機層を集
めて硫酸ナトリウムで乾燥し、減圧留去した。残香をシ
リカゲルカラム(φ2.4X20cm)で分取し、10
%エタノール/クロロホルムで溶出し、酢酸エチルから
結晶化して、3′、5°−0−テトライソプロビルジシ
ロキサニル−2′−デオキシ−2′−メチリデン−5−
ヨウドシチジンを得た。収量169■、収率52.7%
。(4) In 10 ml of acetonitrile under an argon atmosphere, triethylamine 1.51 and 1.2.4-) Riazole 7
60 μm was dissolved and cooled on ice. Phosphorus oxychloride 310#&
was added dropwise, the temperature was returned to room temperature after 30 minutes, the precipitate was filtered off, the compound 321■ obtained in (3) was added to the filtrate, and the mixture was stirred at room temperature for 30 minutes.
Stir for hours. Ammonia gas was passed through sodium hydroxide for 3 hours, and 50a1 of chloroform and 5011 of water were added to separate the layers. The aqueous layer was washed with chloroform, and the organic layers were collected, dried over sodium sulfate, and evaporated under reduced pressure. The residual fragrance was collected using a silica gel column (φ2.4 x 20 cm), and 10
Elution with % ethanol/chloroform and crystallization from ethyl acetate yielded 3',5°-0-tetraisoprobyl disiloxanyl-2'-deoxy-2'-methylidene-5-
Iodocytidine was obtained. Yield 169■, yield 52.7%
.
融点185〜187℃、 Mass (貧/z): 6
07 (M”) 。Melting point 185-187℃, Mass (poor/z): 6
07 (M”).
(5) (4)で得た化合物160■をテトラヒドロ
フラン51に溶解し、フッ化テトラ−n−ブチルアンモ
ニウム1−1を加え、室温で30分間撹拌した。(5) Compound 160 .mu. obtained in (4) was dissolved in 51 ml of tetrahydrofuran, 1-1 of tetra-n-butylammonium fluoride was added, and the mixture was stirred at room temperature for 30 minutes.
メタノール2鶴1を加え、溶媒を減圧留去した。残香を
シリカゲルカラム(φ3.5 X 7. Ocm )で
分取し、20%エタノール/クロロホルムで溶出して、
あめ状物質として、2゛−デオキシ−2°−メチリデン
−5−ヨウドシチジンを得た。収192■、収率97.
3%、融点159〜I61 ’C,Mass (m/z
):365 (M ”)。Two parts and one part of methanol were added, and the solvent was distilled off under reduced pressure. The residual fragrance was collected using a silica gel column (φ3.5 x 7.0 cm) and eluted with 20% ethanol/chloroform.
2'-deoxy-2'-methylidene-5-iodocytidine was obtained as a candy-like substance. Yield 192■, yield 97.
3%, melting point 159-I61'C, Mass (m/z
):365 (M”).
実施例6
(1)5−エチニルウリジン2.1gをピリジン5〇−
に溶解し、水冷下、1.3−ジクロロ−1,1,3,3
−テトライソプロピルジシロキサン2.61を加え3時
間撹拌した。更に、室温に戻し一晩撹拌後メタノール5
mlを加え、溶媒を減圧留去した。残香に酢酸エチル1
001、水100m+を加え、分液し、有機層を2回水
洗後硫酸ナトリウムで乾燥し、溶媒を減圧留去した。残
香をシリカゲルカラム(φ5.OX17cm)で分取し
、25%酢酸エチル/ヘキサンで溶出すると、3°、5
’−0−テトライソプロビルジシロキサニル−5−エチ
ニルウリジンをあわ状物質として得た。収量3.26
g、収率82%、 Mass (m/z): 510
(M ”)。Example 6 (1) 2.1 g of 5-ethynyluridine was mixed with 50-
Dissolved in 1,3-dichloro-1,1,3,3 under water cooling.
- 2.61 g of tetraisopropyldisiloxane was added and stirred for 3 hours. Furthermore, after returning to room temperature and stirring overnight, methanol 5
ml was added, and the solvent was distilled off under reduced pressure. 11 ethyl acetate for residual fragrance
001, 100 m+ of water was added, the layers were separated, and the organic layer was washed twice with water, dried over sodium sulfate, and the solvent was distilled off under reduced pressure. The residual aroma was collected using a silica gel column (φ5.OX17cm) and eluted with 25% ethyl acetate/hexane.
'-0-Tetraisopropyldisiloxanyl-5-ethynyluridine was obtained as a foam. Yield 3.26
g, yield 82%, Mass (m/z): 510
(M”).
(2) (1)で得た化合物2.04gを4当量のク
ロム酸コンプレックス(塩化メチレン40−1中、酸化
クロム1.55 g、ピリジン2.57+*l、無水酢
酸1.55m1)に混合し、室温で40分間撹拌した0
反応液を酢酸エチル2001に滴下し、φ6. OX
1. Ocmのシリカゲルで濾過した。濾液を減圧留去
し、残香を酢酸エチル100Ill、水100+glで
分液した。(2) Mix 2.04 g of the compound obtained in (1) with 4 equivalents of chromic acid complex (1.55 g of chromium oxide, 2.57+*l of pyridine, 1.55 ml of acetic anhydride in 40-1 methylene chloride). and stirred at room temperature for 40 minutes.
The reaction solution was added dropwise to ethyl acetate 2001, and the φ6. OX
1. Filtered through Ocm silica gel. The filtrate was distilled off under reduced pressure, and the residual aroma was separated between 100 Ill of ethyl acetate and 100+ g of water.
有機層を2回洗浄後、硫酸ナトリウムで乾燥し、溶媒を
減圧留去した。残香をシリカゲルカラム(φ3.5X1
5c曹)で分取し、20%酢酸エチル/ヘキサンで溶出
し、3°、5’−0−テトライソプロビルジシロキサニ
ル−2゛−オキソ−5−エチニルウリジンをあめ状物質
として得た。収11.62g、収率81%、 Mass
(m/z): 508 (M”)。The organic layer was washed twice, dried over sodium sulfate, and the solvent was distilled off under reduced pressure. Remove the residual fragrance using a silica gel column (φ3.5X1
5c carbon dioxide) and eluted with 20% ethyl acetate/hexane to obtain 3°, 5'-0-tetraisoprobyl disiloxanyl-2'-oxo-5-ethynyl uridine as a candy-like substance. Yield 11.62g, yield 81%, Mass
(m/z): 508 (M”).
(3) I化メチルトリフヱニルホスホニウム4.2
9gをテトラヒドロフラン40m1にアルゴン気流下懸
濁し、水冷下、n−ブチルリチウム7.58m1を滴下
した。室温に戻し、1時間撹拌後、水冷し、(2)で得
た化合物1.52 gのテトラヒドロフランlロー1溶
液を滴下し、30分後室温に戻した。6時間後、IN臭
化アンモニウムで中和し、酢酸エチル1001、水10
01を加え分液した。有機層を2回水洗後、硫酸ナトリ
ウムで乾燥し、減圧留去した。残香をシリカゲルカラム
(φ3.5X20c曹)で分取し、20%酢酸エチル/
ヘキサンで溶出すると、3゛、5″−〇−テトライソプ
ロビルジシロキサニル−2“−デオキシ−2゛−メチリ
デン−5−エチニルウリジンをあめ状物質として得た。(3) Methyltriphenylphosphonium I 4.2
9 g was suspended in 40 ml of tetrahydrofuran under an argon stream, and 7.58 ml of n-butyllithium was added dropwise under water cooling. After returning to room temperature and stirring for 1 hour, the mixture was cooled with water, and a solution of 1.52 g of the compound obtained in (2) in 1 mL of tetrahydrofuran was added dropwise, and after 30 minutes, the mixture was returned to room temperature. After 6 hours, neutralize with IN ammonium bromide, add 100 parts of ethyl acetate and 10 parts of water.
01 was added and the liquid was separated. The organic layer was washed twice with water, dried over sodium sulfate, and evaporated under reduced pressure. The residual aroma was collected using a silica gel column (φ3.5 x 20c carbon dioxide), and 20% ethyl acetate/
Elution with hexane gave 3',5'-0-tetraisopropyldisiloxanyl-2'-deoxy-2'-methylidene-5-ethynyl uridine as a candy-like material.
収11.12g1収率74%。Mass (s/z):
506 (M”) a(4) (3)で得た化合物
500■をテトラヒドロフランLOslに溶解し、フッ
化テトラー1−ブチルアンモニウム2.2111を加え
、室温で20分間撹拌した、酢酸で中和し、溶媒を減圧
留去した。残香をシリカゲルカラム(φ2.4X18c
+a)で分取し、10%エタノール/クロロホルムで溶
出し、エタノール−ヘキサンから結晶化して、2°−デ
オキシ−2゛−メチリデン−5〜エチニルウリジンを得
た。Yield: 11.12g/yield: 74%. Mass (s/z):
506 (M") a(4) 500 μ of the compound obtained in (3) was dissolved in tetrahydrofuran LOsl, 2.2111 tetra-1-butylammonium fluoride was added, and the mixture was stirred at room temperature for 20 minutes. Neutralized with acetic acid. The solvent was distilled off under reduced pressure.The residual aroma was removed using a silica gel column (φ2.4
+a), eluted with 10% ethanol/chloroform, and crystallized from ethanol-hexane to obtain 2°-deoxy-2′-methylidene-5~ethynyluridine.
収量230■、収率87%、融点172〜174”C,
Mass (m/z): 264 (M”) 。Yield 230■, yield 87%, melting point 172-174"C,
Mass (m/z): 264 (M”).
実施例7
(1)アセトニトリル10m1中、アルゴン気流下トリ
エチルアミン1.5mlと1.2.4− )リアゾール
760■を溶解し、氷冷した。オキシ塩化リン31OP
tを滴下し、30分後室温に戻して更に30分間撹拌し
た。沈澱を濾去し、濾液に実施例8(3)で得た3”、
5°−0−テトライソプロビルジシロキサニル2゛−デ
オキシ−2°−メチリデン−5−エチニルウリジン50
0gを加え室温で3時間撹拌した。Example 7 (1) In 10 ml of acetonitrile under an argon stream, 1.5 ml of triethylamine and 760 ml of 1.2.4-) lyazole were dissolved and cooled on ice. Phosphorus oxychloride 31OP
After 30 minutes, the mixture was returned to room temperature and stirred for an additional 30 minutes. The precipitate was removed by filtration, and the 3" obtained in Example 8 (3) was added to the filtrate.
5°-0-tetraisopropyldisiloxanyl 2′-deoxy-2°-methylidene-5-ethynyluridine 50
0 g was added and stirred at room temperature for 3 hours.
水酸化ナトリウムを通したアンモニアガスを2時間通じ
、クロロホルム80−1、水80a+1を加えて分液し
た。水層をクロロホルムで洗い、クロロホルム層を集め
て硫酸ナトリウムで乾燥後、減圧留去した。残香をシリ
カゲルカラム(φ3.5X14C+a)で分取し、75
%酢酸エチル/ヘキサンで溶出すると、あめ状物質とし
て、3”、5°−〇−テトライソプロビルジシロキサニ
ル−2゛−デオキシ−2゛−メチリデン−5−エチニル
シチジンを得た。Ammonia gas was passed through sodium hydroxide for 2 hours, and chloroform 80-1 and water 80a+1 were added to separate the layers. The aqueous layer was washed with chloroform, the chloroform layers were collected, dried over sodium sulfate, and then evaporated under reduced pressure. The residual fragrance was collected using a silica gel column (φ3.5×14C+a), and 75
Elution with % ethyl acetate/hexane gave 3'',5'-0-tetraisoprobyldisiloxanyl-2'-deoxy-2'-methylidene-5-ethynylcytidine as a candy.
収131 (l■、収率62%、 Mass (m/z
): 505 (M”)。Yield 131 (l■, yield 62%, Mass (m/z
): 505 (M”).
(2) (1)で得た化合物300■をテトラヒドロ
フラン10m1に溶解し、フッ化テトラーn−ブチルア
ンモニウム1.2@lを加え、室温で30分間撹拌した
。メタノール2+wlを加え、溶媒を減圧留去した。(2) 300 μl of the compound obtained in (1) was dissolved in 10 ml of tetrahydrofuran, 1.2@l of tetra-n-butylammonium fluoride was added, and the mixture was stirred at room temperature for 30 minutes. 2+wl of methanol was added and the solvent was distilled off under reduced pressure.
残香をシリカゲルカラム(φ2.OX12cm)で分取
し、20%エタノール/クロロホルムで溶出すると、あ
め状物質として、2′−デオキシ−2゛−メチリデン−
5−エチニルシチジンを得た。収量9.7■、収率62
%。The residual aroma was collected using a silica gel column (φ2.OX12cm) and eluted with 20% ethanol/chloroform to produce 2'-deoxy-2'-methylidene- as a candy-like substance.
5-ethynylcytidine was obtained. Yield 9.7■, Yield 62
%.
実施例8
(1)実施例6(1)で得た3’、 5’−0−テトラ
イソプロビルジシロキサニル−5−エチニルウリジン3
.8gをメタノール50m1に溶解し、10%パラジウ
ム炭素100■を懸濁し20psiで4時間中圧接触還
元を行なった0反応液をセライト濾過し溶媒を減圧留去
した。残香をシリカゲルカラム(φ3、OX20cm)
で分取し、33%酢酸エチル/ヘキサンで溶出すると、
3゛、5′−〇−テトライソプロビルジシロキサニル−
5−エチルウリジンをあめ状物質として得た。収13.
22■、収率84%。Example 8 (1) 3', 5'-0-tetraisoprobyl disiloxanyl-5-ethynyl uridine 3 obtained in Example 6 (1)
.. 8 g was dissolved in 50 ml of methanol, 100 μl of 10% palladium on carbon was suspended, and medium pressure catalytic reduction was carried out at 20 psi for 4 hours. The reaction solution was filtered through Celite and the solvent was distilled off under reduced pressure. Remove residual fragrance using silica gel column (φ3, OX20cm)
When fractionated and eluted with 33% ethyl acetate/hexane,
3゛,5′-〇-tetraisoprobyl disiloxanyl-
5-Ethyluridine was obtained as a candy-like substance. Collection 13.
22■, yield 84%.
Mass (m/z): 514 (Mつ。Mass (m/z): 514 (M.
(2) (1)で得た化合物3.15 gを4当蓋の
クロム酸コンプレックス(塩化メチレン60+ml中、
酸化クロム2.37g2ピリジン3.93m1.無水酢
酸2.371)に混合し、室温で50分間撹拌した0反
応液を酢酸エチル300m1に滴下し、φ6.0X10
c+mのシリカゲルで濾過した。濾液を濃縮し、酢酸エ
チル100s+1、水1001を加えて分液した。有機
層を2回水洗した後、硫酸ナトリウムで乾燥し、減圧留
去した。残香をシリカゲルカラム(φ3.5X15C1
m)で分取し、20%酢酸エチル/−・キサンで溶出し
、酢酸エチル−ヘキサンから結晶化して、3”、5“−
0−テトライソプロビルジシロキサニル−2°−オキソ
−5−エチルウリジンを得た。(2) 3.15 g of the compound obtained in (1) was mixed with 4 caps of chromic acid complex (in 60+ml of methylene chloride,
Chromium oxide 2.37g2 Pyridine 3.93ml1. The reaction solution, which was mixed with acetic anhydride (2.371) and stirred at room temperature for 50 minutes, was added dropwise to 300 ml of ethyl acetate, and the
Filtered through c+m silica gel. The filtrate was concentrated, and 100 s+1 ethyl acetate and 100 ml water were added to separate the layers. The organic layer was washed twice with water, dried over sodium sulfate, and evaporated under reduced pressure. Remove the residual fragrance using a silica gel column (φ3.5X15C1
m), eluted with 20% ethyl acetate/- xane, crystallized from ethyl acetate-hexane,
0-tetraisopropyldisiloxanyl-2°-oxo-5-ethyluridine was obtained.
収量2.54g、収率80.8%。融点176〜177
”C,Mass (II/Z): 512 (M”)。Yield: 2.54 g, yield: 80.8%. Melting point 176-177
"C, Mass (II/Z): 512 (M").
元素分析値 Ct x Ha。NzOISigとして二
計算値: C、53,88)1 i 7.86 N 、
5.46実測値: C、53,59H; 8.01
N 、 5.56(3) 臭化メチルトリフェニ
ルホスホニウム5.72gをテトラヒドロフラン50m
1にアルゴン気流下懸濁し、水冷下、n−ブチルリチウ
ム10.1mlを滴下し、室温に戻し、1時間撹拌した
。(2)で得た化合物2.05 gのテトラヒドロフラ
ン15m1溶液を水冷下に滴下し、3時間後室温に戻し
、5時間撹拌した。IN臭化アンモニウムで中和し、酢
酸エチル1501、水150m1を加え分液した。有機
層を2回水洗後、硫酸ナトリウムで乾燥し、減圧留去し
た。残香をシリカゲルカラム(φ3,5×13C1l)
で分取し、20%酢酸エチル/ヘキサンで溶出し、酢酸
エチル−ヘキサンから結晶化して、3゛、5°−0−テ
トライソプロビルジシロキサニル2゛−デオキシ−2°
−メチリデン−5−エチルウリジンを得た。収111.
70g、収率82.7%、融点153〜155 ℃、
Mass (II/2): 510 (M”)
。Elemental analysis value Ct x Ha. Two calculated values as NzOISig: C, 53,88) 1 i 7.86 N,
5.46 Actual value: C, 53,59H; 8.01
N, 5.56 (3) 5.72 g of methyltriphenylphosphonium bromide in 50 m of tetrahydrofuran
1 under an argon atmosphere, 10.1 ml of n-butyllithium was added dropwise under water cooling, the temperature was returned to room temperature, and the mixture was stirred for 1 hour. A solution of 2.05 g of the compound obtained in (2) in 15 ml of tetrahydrofuran was added dropwise under water cooling, and after 3 hours, the mixture was returned to room temperature and stirred for 5 hours. The mixture was neutralized with IN ammonium bromide, and 150 ml of ethyl acetate and 150 ml of water were added to separate the layers. The organic layer was washed twice with water, dried over sodium sulfate, and evaporated under reduced pressure. Remove the residual scent through a silica gel column (φ3,5 x 13C1l)
eluted with 20% ethyl acetate/hexane and crystallized from ethyl acetate/hexane to give 3',5'-0-tetraisopropyldisiloxanyl 2'-deoxy-2'.
-Methylidene-5-ethyluridine was obtained. Collection 111.
70g, yield 82.7%, melting point 153-155°C,
Mass (II/2): 510 (M”)
.
元素分析値 CxaHazNtOhS izとして:計
算値: Ci 56.44 H; 8.29 N
; 5.48実測値: C、56,67Hi 8.
41 N ? 5.36(4) (3)で得た化合
物510■をテトラヒドロフラン101に溶解し、フッ
化テトラ−n−ブチルアンモニウム2.2mlを加え、
室温で30分間撹拌した。酢酸で中和し、溶媒を減圧留
去した。残香をシリカゲルカラム(φ3.OX12cm
)で分取し、6.25%エタノール/クロロホルムで溶
出し、エタノール−ヘキサンで結晶化して、2°−デオ
キシ−2°−メチリデン−5−エチルウリジンを得た。Elemental analysis value as CxaHazNtOhS iz: Calculated value: Ci 56.44 H; 8.29 N
; 5.48 Actual value: C, 56,67Hi 8.
41 N? 5.36(4) Dissolve 510 ml of the compound obtained in (3) in 101 ml of tetrahydrofuran, add 2.2 ml of tetra-n-butylammonium fluoride,
Stirred at room temperature for 30 minutes. The mixture was neutralized with acetic acid, and the solvent was distilled off under reduced pressure. Remove the residual fragrance using a silica gel column (φ3.OX12cm)
), eluted with 6.25% ethanol/chloroform, and crystallized from ethanol-hexane to obtain 2°-deoxy-2°-methylidene-5-ethyluridine.
収N234■、収率87.2%、融点137〜139’
C,Mass (II/2): 268 (Mつ。Yield N234■, yield 87.2%, melting point 137-139'
C, Mass (II/2): 268 (M.
元素分析値 C+ z HIh N z Osとして:
計算値: Ci 53.73 Hi 6.01
N ? 10.44実測値: C; 53.79
H、5,89N i 10.67実施例9
(1)アセトニトリル20−1中、アルゴン気流下トリ
エチルアミン3mlと1.2.4−トリアゾール1.5
2gを溶解し、氷冷した。オキシ塩化リン620Pgを
滴下し、30分後室温に戻して更に30分間撹拌した。Elemental analysis value as C+ z HIh N z Os:
Calculated value: Ci 53.73 Hi 6.01
N? 10.44 Actual value: C; 53.79
H, 5,89N i 10.67 Example 9 (1) 3 ml of triethylamine and 1.5 ml of 1,2,4-triazole under a stream of argon in 20-1 acetonitrile
2g was dissolved and cooled on ice. 620 Pg of phosphorus oxychloride was added dropwise, and after 30 minutes, the mixture was returned to room temperature and stirred for an additional 30 minutes.
沈澱を濾去し、濾液に実施例8(3)で得た、3’、5
’−0−テトライソプロビルジシロキサニル2′−デオ
キシ−2°−メチリデン−5−エチルウリジン1.2g
加え室温で4時間撹拌した。水酸化ナトリウムを通した
アンモニアガスを通じ、クロロホルム10(1+1、水
100m1を加え分液した。The precipitate was filtered off, and the 3',5 obtained in Example 8 (3) was added to the filtrate.
'-0-tetraisopropyldisiloxanyl 2'-deoxy-2°-methylidene-5-ethyluridine 1.2 g
The mixture was added and stirred at room temperature for 4 hours. Ammonia gas was passed through sodium hydroxide, and chloroform 10 (1+1) and water 100 ml were added to separate the layers.
水層をクロロホルムで洗い、クロロホルム層を集めて硫
酸ナトリウムで乾燥後、減圧留去した。残香をシリカゲ
ルカラム(φ3.5X20c11)で分取し、9%エタ
ノール/クロロホルムで溶出し、酢酸エチル−ヘキサン
より結晶化して、3°、5”−〇−テトライソプロピル
ジシロキサニル−2゛−デオキシ−2°−メチリデン−
5−エチルシチジンを得た。収量1.0g、収率83.
3%、融点197〜200”C,Mass (s/z
): 509 (M”) *(2) (1)で
得た化合物900■をテトラヒドロフラン10m1に溶
解し、フッ化テトラ−n−ブチルアンモニウム41を加
え、室温で30分間撹拌した。The aqueous layer was washed with chloroform, the chloroform layers were collected, dried over sodium sulfate, and then evaporated under reduced pressure. The residual aroma was collected using a silica gel column (φ3.5×20c11), eluted with 9% ethanol/chloroform, and crystallized from ethyl acetate-hexane to give 3°, 5”-〇-tetraisopropyldisiloxanyl-2゛- Deoxy-2°-methylidene-
5-ethylcytidine was obtained. Yield 1.0g, yield 83.
3%, melting point 197-200"C, Mass (s/z
): 509 (M") *(2) 900 .mu. of the compound obtained in (1) was dissolved in 10 ml of tetrahydrofuran, 41 of tetra-n-butylammonium fluoride was added, and the mixture was stirred at room temperature for 30 minutes.
メタノール5mlを加え溶媒を減圧留去した。残香をシ
リカゲルカラム(φ3.5X10cm)で分取し、20
%エタノール/クロロホルムで溶出し、エタノール−酢
酸エチルから結晶化して、2゛−デオキシ−2°−メチ
リデン−5−エチルシチジンを得た。5 ml of methanol was added and the solvent was distilled off under reduced pressure. The residual fragrance was collected using a silica gel column (φ3.5 x 10 cm), and 20
Elution with % ethanol/chloroform and crystallization from ethanol-ethyl acetate gave 2'-deoxy-2'-methylidene-5-ethylcytidine.
収N402■、収率85.4%、融点194〜196℃
。Yield N402■, yield 85.4%, melting point 194-196℃
.
Mass (+a/z): 267 (M’) 。Mass (+a/z): 267 (M').
実施例10
2°−デオキシ−2゛−メチリデン−5−フルオロシチ
ジンとオキシ塩化リンとを用いて常法にしたがって反応
・処理すると、2゛−デオキシ−2°−メチリデン−5
−フルオロシチジン−5°−リン酸が得られる。Example 10 When 2°-deoxy-2′-methylidene-5-fluorocytidine and phosphorus oxychloride are reacted and treated according to a conventional method, 2′-deoxy-2′-methylidene-5
-Fluorocytidine-5°-phosphoric acid is obtained.
製剤例1
実施例1の化合物 50.0■微粉末
セルロース 25.0 mg乳糖
49.5■
スターチ 40.0■タルク
5.0■ステアリン
酸マグネシウム 0.5■からなる錠剤。Formulation Example 1 Compound of Example 1 50.0 ■ Finely powdered cellulose 25.0 mg Lactose
Tablet consisting of 49.5■ Starch 40.0■ Talc 5.0■ Magnesium stearate 0.5■.
所望により糖衣処理またはフィルムコート処理を施すこ
とによって糖衣錠またはフィルムコート錠とすることが
できる。Sugar-coated tablets or film-coated tablets can be obtained by sugar-coating or film-coating, if desired.
製剤例2
実施例1の化合物 50.0■乳糖
50.0■
スターチ 15.0■タルク
5.0■の組成をカ
プセルに充填してなるカプセル剤。Formulation Example 2 Compound of Example 1 50.0■Lactose
50.0 ■ Starch 15.0 ■ Talc 5.0 ■ Capsules filled with the following composition.
製剤例3
実施例1の化合物 10%乳糖
80%
スターチ 10%からなる細
粒剤。Formulation Example 3 Compound of Example 1 10% Lactose
Fine granules consisting of 80% starch and 10%.
製剤例4
実施例1の化合物 10%乳糖
55%
微粉末セルロース 20%スターチ
15%からなる顆粒剤。Formulation Example 4 Compound of Example 1 10% Lactose
55% finely powdered cellulose 20% starch
Granules consisting of 15%.
製剤例5
実施例1の化合物 50.0■グルコ
ース 100.0■を精製水に
溶かして、全量2+alの注射溶液とする。Formulation Example 5 50.0 μg of the compound of Example 1 and 100.0 μg of glucose are dissolved in purified water to prepare an injection solution with a total volume of 2+al.
製剤例6
実施例1の化合物 1001gウイf
7”ソール” 815 950mgウイテプ
ソール@ E75 950■からなる坐剤、
ただし、ウイテプソールはヴイッテン社(西ドイツ)所
有の登録商標である。Formulation Example 6 Compound of Example 1 1001g
7"Sole" 815 950mg Suppository consisting of Uitepsol @ E75 950■,
However, Uitepsol is a registered trademark owned by Wuitten (West Germany).
製剤例7
実施例1の化合物 2gバラヒド
ロキシ安息香酸エチル 0.025 gバラヒドロキ
シ安息香酸プロピル 0.015gラウリル硫酸ナトリ
ウム 1.5gプロピレングリコール
12.0gステアリルアルコール
22.0 g白色ワセリン
25.0 gの組成を精製水に溶かして、全IJ 1
00. Ogの親水軟膏とする。Formulation Example 7 Compound of Example 1 2 g Ethyl hydroxybenzoate 0.025 g Propyl hydroxybenzoate 0.015 g Sodium lauryl sulfate 1.5 g Propylene glycol
12.0g stearyl alcohol
22.0 g white petrolatum
Dissolve 25.0 g of the composition in purified water to obtain a total of IJ 1
00. Og's hydrophilic ointment.
以下の薬理実験により、本発明化合物がすぐれた抗腫瘍
作用を有することを説明する。The following pharmacological experiments demonstrate that the compounds of the present invention have excellent antitumor effects.
薬理実験:各種培養腫瘍細胞のin vitroでの増
殖に及ぼす影響
各種培養腫瘍細胞(104個)および被検化合物を含む
培養液を96穴プレー) (FALCON 3072)
の各人に100#jになるように加え、37°C,5%
Cot、−95%空気下で72時間培養した。Pharmacological experiment: Effect on in vitro proliferation of various cultured tumor cells (96-well plate with culture solution containing various cultured tumor cells (104 cells) and test compound) (FALCON 3072)
Add to each person to make 100#j, 37°C, 5%
Cot, cultured under −95% air for 72 hours.
培養後、MTT (3−(4,5−ジメチル−チアゾー
ル−2−イル)−2,5−ジフェニルテトラゾリウムブ
ロマイド〕溶液(5■/m1)を1OPIずつ各人に添
加し、さらに4時間37°C15%C0X−95%空気
下でインキュベートし、10%ドデシル硫酸ナトリウム
−0,0IN塩酸溶液の100μを各人に加えた。−晩
放置後マイクロプレート光度計を用いて570nmにお
ける吸光度を測定し細胞数の指標とした。以下の式より
抑制率を算出し、50%抑制する被検化合物の濃度(I
C,。)を求めた。After incubation, 1 OPI of MTT (3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyltetrazolium bromide) solution (5 μ/ml) was added to each person, and the cells were incubated at 37° for another 4 hours. Cells were incubated under 15%C0X-95% air and 100μ of 10% sodium dodecyl sulfate-0.0IN hydrochloric acid solution was added to each person.After standing overnight, the absorbance at 570nm was measured using a microplate photometer. The inhibition rate was calculated from the following formula, and the concentration of the test compound that inhibited 50% (I
C. ) was sought.
第1表から明らかなように、本発明化合物は各種培養腫
瘍細胞に対し、すぐれた増殖抑制効果を示し、制がん剤
として有用である。As is clear from Table 1, the compounds of the present invention exhibit excellent growth-inhibiting effects on various cultured tumor cells and are useful as anticancer agents.
なお、被検化合物には2′−デオキシ−2゜メチリデン
−5−フルオロシチジンを蒸留水に溶解して用いた。ま
た、各種腫瘍細胞株は1o%FC8を含むRPM116
40培地(日永製薬)で培養した。The test compound used was 2'-deoxy-2゜methylidene-5-fluorocytidine dissolved in distilled water. In addition, various tumor cell lines are RPM116 containing 1o% FC8.
40 medium (Hinaga Pharmaceutical Co., Ltd.).
得られたIC,。値(pg/ml)を第1表にまとめた
。The resulting IC. The values (pg/ml) are summarized in Table 1.
第1表Table 1
Claims (5)
アミノの場合、R^2はハロゲン、炭素数2〜4個のア
ルキニルまたは低級アルキルを、R^1が水酸基の場合
、R^2は炭素数2〜4個のアルキル、炭素数2〜4個
のアルキニルまたはハロアルキルを、R^3は水素また
はリン酸残基を示す。)により表わされる2’−メチリ
デンピリミジンヌクレオシド化合物またはその塩。(1) General formula ▲ There are mathematical formulas, chemical formulas, tables, etc. When R^1 is a hydroxyl group, R^2 is an alkyl having 2 to 4 carbon atoms, alkynyl or haloalkyl having 2 to 4 carbon atoms, and R^3 is hydrogen or a phosphoric acid residue. A 2'-methylidenepyrimidine nucleoside compound or a salt thereof represented by:
る一般式 ▲数式、化学式、表等があります▼ (式中、R^2はハロゲン、炭素数2〜4個のアルキル
、炭素数2〜4個のアルキニルまたはハロアルキルを、
R^3は水素またはリン酸残基を示す。)により表わさ
れる請求項(1)記載の化合物またはその塩。(2) When R^1 is a hydroxyl group, its tautomer is the general formula ▲ Numerical formula, chemical formula, table, etc. ▼ (In the formula, R^2 is halogen, alkyl having 2 to 4 carbon atoms, Alkynyl or haloalkyl having 2 to 4 carbon atoms,
R^3 represents hydrogen or a phosphoric acid residue. ) or a salt thereof according to claim (1).
ロシチジンまたはその塩。(3) 2'-deoxy-2'-methylidene-5-fluorocytidine or a salt thereof.
することを特徴とする制がん剤。(4) An anticancer agent containing the compound according to claim (1) as an active ingredient.
ロシチジンまたはその塩を有効成分として含有してなる
制がん剤。(5) An anticancer agent containing 2'-deoxy-2'-methylidene-5-fluorocytidine or a salt thereof as an active ingredient.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP1217719A JP2784941B2 (en) | 1988-08-25 | 1989-08-23 | 2'-methylidenepyrimidine nucleoside compound and pharmaceutical use thereof |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP21206188 | 1988-08-25 | ||
JP63-212061 | 1988-08-25 | ||
JP1217719A JP2784941B2 (en) | 1988-08-25 | 1989-08-23 | 2'-methylidenepyrimidine nucleoside compound and pharmaceutical use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH02138292A true JPH02138292A (en) | 1990-05-28 |
JP2784941B2 JP2784941B2 (en) | 1998-08-13 |
Family
ID=26518978
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP1217719A Expired - Lifetime JP2784941B2 (en) | 1988-08-25 | 1989-08-23 | 2'-methylidenepyrimidine nucleoside compound and pharmaceutical use thereof |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2784941B2 (en) |
-
1989
- 1989-08-23 JP JP1217719A patent/JP2784941B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
JP2784941B2 (en) | 1998-08-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5213194B2 (en) | 4'-C-substituted-2-haloadenosine derivatives | |
US20030144502A1 (en) | Pyrido[2,3-d]pyrimidine and pyrimido[4,5-d]pyrimidine nucleosides | |
JPS63239294A (en) | Novel adenosine derivative and medicinal composition containing said compound as active ingredient | |
KR910008800B1 (en) | 2'-alkylidenepyrimidine nucleoside derivatives process for their preparation and their use | |
JP2008069182A (en) | 4'-c-substituted-2-haloadenosine derivative | |
JPH09504541A (en) | 5-fluorouracil derivative | |
JPH0853490A (en) | 2'-deoxy-2',2'-dihalogeno-4'-thionucleoside | |
EP0155164B1 (en) | Novel cyanoimidazole nucleoside derivatives | |
US4925930A (en) | Synthesis and anti-leukemic activity of alkyl-1-(β-D-ribofuranosyl)[1,2,4]triazole-3-carboximidates | |
KR0136869B1 (en) | 2'-methylidenepyrimidine nucleoside compounds, their use and method for production thereof | |
JPH02138292A (en) | 2'-methylidenepyrimidine nucleoside compound and drug use thereof | |
JPH0129800B2 (en) | ||
JPH0692986A (en) | Substituted nucleoside derivative, its production and medicinal composition containing it | |
US5401726A (en) | 2'methylidenepyrimidine nucleoside compounds, their use and method for production thereof | |
EP0572669A1 (en) | 1-B(beta)-D-Arabinofuranosyl-(E)-5-(2-halogenovinyl)-uracil-derivative | |
JP2004505899A (en) | 5'-Deoxy-N- (substituted oxycarbonyl) -5-fluorocytosine and derivatives thereof, method for producing the same, and anticancer composition containing the same as an active ingredient | |
JPH02157292A (en) | 2'-deoxy-2'-methylidenepyrimidene nucleotide compound | |
JP4211901B2 (en) | 4'-methyl nucleoside compounds | |
JPH0340038B2 (en) | ||
US3899482A (en) | 2,2{40 -Anhydro-1-{62 D-arabinofuranosyl-5-fluorocytosine salts and process 2 | |
JPH0363224A (en) | Sugar derivative of protocatechuic aldehydes | |
JPH0340039B2 (en) | ||
JPH02262588A (en) | Mew phosphonic acid derivative | |
JPH0413328B2 (en) | ||
JPH0340036B2 (en) |